NeueHealth (NEUE) 10-Q 9 Aug 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2023	Aug. 02, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-40537
Entity Registrant Name	BRIGHT HEALTH GROUP, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-4991296
Entity Address, Address Line One	8000 Norman Center Drive, Suite 900
Entity Address, City or Town	Minneapolis
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55437
City Area Code	612
Local Phone Number	238-1321
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	BHG
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,972,092
Entity Central Index Key	0001671284
Amendment Flag	false
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents		$ 107,660	$ 217,006
Short-term investments		156	869
Accounts receivable, net of allowance of $7,653 and $6,098, respectively		27,633	19,576
ACO REACH performance year receivable		623,609	99,181
Current assets of discontinued operations (Note 14)		3,030,870	3,187,464
Prepaids and other current assets		61,198	46,538
Total current assets		3,851,126	3,570,634
Other assets:
Long-term investments		344	5,401
Property, equipment and capitalized software, net		18,474	21,298
Goodwill		401,385	401,385
Intangible assets, net		99,084	104,952
Long-term assets of discontinued operations (Note 14)		0	529,117
Other non-current assets		22,740	32,265
Total other assets		542,027	1,094,418
Total assets		4,393,153	4,665,052
Current liabilities:
Medical costs payable		179,855	116,021
Accounts payable		18,476	18,714
ACO REACH performance year obligation		474,700	0
Short-term borrowings		303,947	303,947
Current liabilities of discontinued operations (Note 14)		2,584,890	3,157,236
Other current liabilities		73,221	97,241
Total current liabilities		3,635,089	3,693,159
Other liabilities		28,792	32,208
Total liabilities		3,663,881	3,725,367
Commitments and contingencies (Note 9)
Redeemable noncontrolling interests		244,561	219,758
Redeemable Series A and B preferred stock		920,417	920,417
Shareholders’ equity (deficit):
Common stock, $0.0001 par value; 3,000,000,000 shares authorized in 2023 and 2022; 7,972,033 and 7,878,394 shares issued and outstanding in 2023 and 2022*, respectively	[1]	1	1
Additional paid-in capital		3,021,430	2,972,333
Accumulated deficit		(3,444,238)	(3,156,395)
Accumulated other comprehensive loss		(899)	(4,429)
Treasury Stock, at cost, 31,526 shares at June 30, 2023, and December 31, 2022*, respectively	[1]	(12,000)	(12,000)
Total shareholders’ equity (deficit)		(435,706)	(200,490)
Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders’ equity (deficit)		$ 4,393,153	$ 4,665,052
Common stock, shares authorized (in shares)		3,000,000,000	3,000,000,000
Redeemable Series A preferred stock
Current liabilities:
Redeemable Series A and B preferred stock		$ 747,481	$ 747,481
Redeemable Series B preferred stock
Current liabilities:
Redeemable Series A and B preferred stock		$ 172,936	$ 172,936
[1]*Shares have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 80 reverse stock split

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accounts receivable, allowance for credit loss	$ 7,653	$ 6,098
Redeemable preferred stock, shares outstanding (in shares)	925,000	925,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	3,000,000,000	3,000,000,000
Common stock, shares issued (in shares)	7,972,033	7,878,394
Common stock, shares outstanding (in shares)	7,972,033	7,878,394
Treasury stock, at cost (in shares)	31,526	31,526
Series A Preferred Stock
Redeemable preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Redeemable preferred stock, shares authorized (in shares)	750,000	750,000
Redeemable preferred stock, shares issued (in shares)	750,000	750,000
Redeemable preferred stock, shares outstanding (in shares)	750,000	750,000
Series B Preferred Stock
Redeemable preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Redeemable preferred stock, shares authorized (in shares)	175,000	175,000
Redeemable preferred stock, shares issued (in shares)	175,000	175,000
Redeemable preferred stock, shares outstanding (in shares)	175,000	175,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Loss) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues [Abstract]
ACO REACH revenue		$ 236,994	$ 137,205	$ 476,801	$ 320,002
Revenue, Product and Service [Extensible Enumeration]		Service [Member]	Service [Member]	Service [Member]	Service [Member]
Investment income (loss)		$ 2	$ (16,238)	$ 10	$ (57,149)
Total revenue		297,982	149,340	598,532	330,104
Operating expenses:
Medical costs		245,160	130,793	505,280	310,249
Operating costs		70,280	78,997	149,798	175,785
Restructuring charges		1,285	2,793	1,586	9,657
Depreciation and amortization		4,671	8,276	10,154	16,336
Total operating expenses		321,396	220,859	666,818	512,027
Operating loss		(23,414)	(71,519)	(68,286)	(181,923)
Interest expense		9,170	337	16,957	1,530
Other income		0	2	0	2
Loss from continuing operations before income taxes		(32,584)	(71,858)	(85,243)	(183,455)
Income tax expense		(892)	2,904	367	12,885
Net loss from continuing operations		(31,692)	(74,762)	(85,610)	(196,340)
Loss from discontinued operations, net of tax (Note 14)		(56,935)	(176,568)	(172,478)	(235,619)
Net Loss		(88,627)	(251,330)	(258,088)	(431,959)
Net earnings from continuing operations attributable to noncontrolling interests		(24,205)	(23,336)	(29,755)	(37,941)
Net loss attributable to Bright Health Group, Inc. common shareholders		$ (125,005)	$ (284,127)	$ (311,910)	$ (488,299)
Basic and diluted loss per share attributable to Bright Health Group, Inc. common shareholders
Continuing operations, basic (in dollars per share)		$ (8.55)	$ (13.68)	$ (17.59)	$ (32.14)
Continuing operations, diluted (in dollars per share)		(8.55)	(13.68)	(17.59)	(32.14)
Discontinued operations, basic (in dollars per share)		(7.15)	(22.45)	(21.76)	(29.97)
Discontinued operations, diluted (in dollars per share)		(7.15)	(22.45)	(21.76)	(29.97)
Net loss per share attributable to common stockholders, basic (in dollars per share)		(15.70)	(36.13)	(39.35)	(62.11)
Net loss per share attributable to common stockholders, diluted (in dollars per share)		$ (15.70)	$ (36.13)	$ (39.35)	$ (62.11)
Basic weighted-average common shares outstanding (in shares)	[1]	7,962	7,865	7,928	7,862
Diluted weighted-average common shares outstanding (in shares)	[1]	7,962	7,865	7,928	7,862
Series A Preferred Stock
Operating expenses:
Series A and B preferred stock dividend accrued		$ (9,942)	$ (9,461)	$ (19,656)	$ (18,399)
Series B Preferred Stock
Operating expenses:
Series A and B preferred stock dividend accrued		(2,231)	0	(4,411)	0
Capitated revenue
Revenues [Abstract]
Revenue		49,764	17,641	99,312	46,289
Service revenue
Revenues [Abstract]
Revenue		$ 11,222	$ 10,732	$ 22,409	$ 20,962
[1]*Shares have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 80 reverse stock split

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (88,627)	$ (251,330)	$ (258,088)	$ (431,959)
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Unrealized investment holding gains (losses) arising during the year, net of tax of $0 and $0, respectively	20	(21,469)	1,749	(49,558)
Less: reclassification adjustments for investment (losses) gains, net of tax of $0 and $0, respectively	(1,317)	(758)	(1,781)	(2,507)
Other comprehensive (loss) income	1,337	(20,711)	3,530	(47,051)
Comprehensive loss	(87,290)	(272,041)	(254,558)	(479,010)
Comprehensive loss attributable to noncontrolling interests	(24,205)	(23,336)	(29,755)	(37,941)
Comprehensive loss attributable to Bright Health Group, Inc. common shareholders	$ (111,495)	$ (295,377)	$ (284,313)	$ (516,951)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Supplemental Income Statement Elements [Abstract]
Unrealized investment holding (losses) gains arising during the year, tax	$ 0	$ 0	$ 0	$ 0
Reclassification adjustments for investment gains, tax	$ 0	$ 0	$ 0	$ 0

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Redeemable Preferred Stock and Shareholders’ Equity (Deficit) - USD ($) $ in Thousands		Total	Common Stock		Additional Paid-In Capital	Retained Earnings (Deficit)	Accumulated Other Comprehensive Income (Loss)	Treasury Stock
Beginning balance (in shares) at Dec. 31, 2021		0
Beginning balance at Dec. 31, 2021		$ 0
Redeemable Preferred Stock
Issuance of preferred stock (in shares)		750,000
Issuance of preferred stock		$ 747,481
Ending balance (in shares) at Mar. 31, 2022		750,000
Ending balance at Mar. 31, 2022		$ 747,481
Beginning balance (in shares) at Dec. 31, 2021	[1]		7,858,000
Beginning balance at Dec. 31, 2021		1,145,120	$ 1		$ 2,861,305	$ (1,700,851)	$ (3,335)	$ (12,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(195,234)				(195,234)
Issuance of common stock (in shares)	[1]		5,000
Issuance of common stock		257			257
Share-based compensation		32,921			32,921
Other comprehensive loss		(26,340)					(26,340)
Ending balance (in shares) at Mar. 31, 2022	[1]		7,863,000
Ending balance at Mar. 31, 2022		$ 956,724	$ 1		2,894,483	(1,896,085)	(29,675)	(12,000)
Beginning balance (in shares) at Dec. 31, 2021		0
Beginning balance at Dec. 31, 2021		$ 0
Ending balance (in shares) at Jun. 30, 2022		750,000
Ending balance at Jun. 30, 2022		$ 747,481
Beginning balance (in shares) at Dec. 31, 2021	[1]		7,858,000
Beginning balance at Dec. 31, 2021		1,145,120	$ 1		2,861,305	(1,700,851)	(3,335)	(12,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive loss		(47,051)
Ending balance (in shares) at Jun. 30, 2022	[1]		7,867,000
Ending balance at Jun. 30, 2022		$ 681,982	$ 1		2,915,118	(2,170,751)	(50,386)	(12,000)
Beginning balance (in shares) at Mar. 31, 2022		750,000
Beginning balance at Mar. 31, 2022		$ 747,481
Ending balance (in shares) at Jun. 30, 2022		750,000
Ending balance at Jun. 30, 2022		$ 747,481
Beginning balance (in shares) at Mar. 31, 2022	[1]		7,863,000
Beginning balance at Mar. 31, 2022		956,724	$ 1		2,894,483	(1,896,085)	(29,675)	(12,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(274,666)				(274,666)
Issuance of common stock (in shares)	[1]		4,000
Issuance of common stock		415			415
Share-based compensation		20,220			20,220
Other comprehensive loss		(20,711)					(20,711)
Ending balance (in shares) at Jun. 30, 2022	[1]		7,867,000
Ending balance at Jun. 30, 2022		$ 681,982	$ 1		2,915,118	(2,170,751)	(50,386)	(12,000)
Beginning balance (in shares) at Dec. 31, 2022		925,000
Beginning balance at Dec. 31, 2022		$ 920,417
Ending balance (in shares) at Mar. 31, 2023		925,000
Ending balance at Mar. 31, 2023		$ 920,417
Beginning balance (in shares) at Dec. 31, 2022		7,878,394	7,878,000	[2]
Beginning balance at Dec. 31, 2022		$ (200,490)	$ 1		2,972,333	(3,156,395)	(4,429)	(12,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(175,011)				(175,011)
Issuance of common stock (in shares)	[2]		74,000
Issuance of common stock		1			1
Share-based compensation		33,320			33,320
Other comprehensive loss		2,193					2,193
Ending balance (in shares) at Mar. 31, 2023	[2]		7,952,000
Ending balance at Mar. 31, 2023		$ (339,987)	$ 1		3,005,654	(3,331,406)	(2,236)	(12,000)
Beginning balance (in shares) at Dec. 31, 2022		925,000
Beginning balance at Dec. 31, 2022		$ 920,417
Ending balance (in shares) at Jun. 30, 2023		925,000
Ending balance at Jun. 30, 2023		$ 920,417
Beginning balance (in shares) at Dec. 31, 2022		7,878,394	7,878,000	[2]
Beginning balance at Dec. 31, 2022		$ (200,490)	$ 1		2,972,333	(3,156,395)	(4,429)	(12,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive loss		$ 3,530
Ending balance (in shares) at Jun. 30, 2023		7,972,033	7,972,000	[2]
Ending balance at Jun. 30, 2023		$ (435,706)	$ 1		3,021,430	(3,444,238)	(899)	(12,000)
Beginning balance (in shares) at Mar. 31, 2023		925,000
Beginning balance at Mar. 31, 2023		$ 920,417
Ending balance (in shares) at Jun. 30, 2023		925,000
Ending balance at Jun. 30, 2023		$ 920,417
Beginning balance (in shares) at Mar. 31, 2023	[2]		7,952,000
Beginning balance at Mar. 31, 2023		(339,987)	$ 1		3,005,654	(3,331,406)	(2,236)	(12,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(112,832)				(112,832)
Issuance of common stock (in shares)	[2]		20,000
Issuance of common stock		1			1
Share-based compensation		15,775			15,775
Other comprehensive loss		$ 1,337					1,337
Ending balance (in shares) at Jun. 30, 2023		7,972,033	7,972,000	[2]
Ending balance at Jun. 30, 2023		$ (435,706)	$ 1		$ 3,021,430	$ (3,444,238)	$ (899)	$ (12,000)
[1]*Shares have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 80 reverse stock split[2]*Shares have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 80 reverse stock split

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (258,088)	$ (431,959)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	16,026	26,270
Impairment of intangible assets	0	6,720
Share-based compensation	49,095	53,141
Deferred income taxes	873	1,154
Unrealized loss on equity securities	0	57,151
Amortization of investments	(14,173)	2,748
Other, net	3,891	1,834
Changes in assets and liabilities, net of acquired assets and liabilities:
Accounts receivable	6,284	(31,404)
ACO REACH performance year receivable	(524,428)	(396,104)
Other assets	57,846	(60,991)
Medical cost payable	(567,932)	231,899
Risk adjustment payable	10,925	916,713
Accounts payable and other liabilities	(111,174)	35,312
Unearned revenue	132,129	3,577
ACO REACH performance year obligation	474,700	310,603
Net cash (used in) provided by operating activities	(724,026)	726,664
Cash flows from investing activities:
Purchases of investments	(828,546)	(1,140,896)
Proceeds from sales, paydown, and maturities of investments	988,749	204,775
Purchases of property and equipment	(2,394)	(15,154)
Business divestitures, net of cash disposed of	(682)	0
Business acquisitions, net of cash acquired	0	(310)
Net cash provided by (used in) investing activities	157,127	(951,585)
Cash flows from financing activities:
Repayments of short-term borrowings	0	(155,000)
Proceeds from issuance of preferred stock	0	747,481
Proceeds from issuance of common stock	2	672
Distributions to noncontrolling interest holders	(4,952)	(1,894)
Net cash (used in) provided by financing activities	(4,950)	591,259
Net (decrease)/ increase in cash and cash equivalents	(571,849)	366,338
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance	1,932,290	1,061,179
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance	1,360,441	1,427,517
Supplemental disclosures of cash flow information:
Changes in unrealized loss on available-for-sale securities in OCI	3,530	(47,051)
Cash paid for interest	$ 7,700	$ 1,168

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION Organization: Bright Health Group, Inc. and subsidiaries (collectively, “Bright Health,” “we,” “our,” “us,” or the “Company”) was founded in 2015 to transform healthcare. Our mission of Making Healthcare Right. Together. is built upon the belief that by aligning the best local resources in healthcare delivery with the financing of care we can drive a superior consumer experience, optimize clinical outcomes, reduce systemic waste, and lower costs. We are a healthcare company building a national Integrated System of Care in close partnership with our Care Partners. Our differentiated approach is built on alignment, focused on the consumer, and powered by technology. Our continuing Consumer Care business operates in two segments: Care Delivery and Care Solutions. Care Delivery provides primary comprehensive services in our clinics with wrap around care management and care coordination activities for those members where we take full or partial risk from a diverse set of payor partners. Care Solutions is our provider enablement business that facilitates care coordination activities using population health tools including technology and data analytics, and provides clinical solutions and care teams to support patients managed through our affiliate partners. Basis of Presentation: The condensed consolidated financial statements include the accounts of Bright Health Group, Inc. and all subsidiaries and controlled companies. All intercompany balances and transactions are eliminated upon consolidation. The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our audited consolidated financial statements, unless the information contained in those disclosures materially changed or is required by GAAP. As such, the condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2022 included in our Form 10-K for the year ended December 31, 2022 (“2022 Form 10-K”). The accompanying condensed consolidated financial statements include all normal recurring adjustments necessary for fair presentation of the interim financial statements. Reportable Segments: During the three months ended June 30, 2023, our reportable segments changed. We now report our operating results through four reportable segments: Care Delivery and Care Solutions within continuing operations and Bright HealthCare - Commercial and Bright HealthCare within discontinued operations. The Care Delivery and Care Solutions segments were formerly within the Consumer Care segment. The updates to our reportable segments conform with the Company’s chief operating decision maker’s (“CODM”) view of our ongoing operations. See Note 10, Segments and Geographic Information , for additional information on our segments. We have reflected this change in all historical periods presented. Discontinued Operations: H aving met the criteria for “held for sale,” we have reflected amounts relating to Bright HealthCare, comprised of the California Medicare Advantage business, as a disposal group classified as held for sale and included as part of discontinued operations in accordance with Accounting Standards Codification (“ASC”) 205-20. The combined assets are valued at the lower of their carrying amount or fair value, net of costs to sell and included as current assets on the Company’s condensed consolidated balance sheet. Assets classified as held for sale are not depreciated. However, interest attributable to the liabilities associated with assets classified as held for sale and other related expenses continue to be accrued. Bright HealthCare is no longer included in the segment reporting following the reclassification to discontinued operations. Refer to Note 14 for further discussion of our discontinued operations inclusive of Bright HealthCare and Bright HealthCare - Commercial. Use of Estimates: The preparation of our condensed consolidated financial statements in conformance with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Our most significant estimates include medical costs payable, ACO REACH performance year receivable and obligation, shared savings and shared losses for our capitation contracts, and valuation and impairment of goodwill and other intangible assets. Actual results could differ from these estimate s. Going Concern: The condensed consolidated financial statements have been prepared in accordance with GAAP applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has a history of operating losses, and we generated a net loss of $258.1 million for the six months ended June 30, 2023. Additionally, the Company experienced negative operating cash flows primarily related to our discontinued Bright HealthCare – Commercial segment for the six months ended June 30, 2023, requiring additional cash to be infused to satisfy statutory capital requirements. The Company’s IFP discontinued operations will continue to experience negative cash flows through the third quarter of 2023, as it pays out the 2022 IFP risk adjustment obligations. Although the Company has sufficient cash to satisfy its IFP risk adjustment obligations in full in certain states, the Company is working with its regulators regarding the status of its obligations in certain other states. In addition, the Company’s $350.0 million revolving credit agreement with a syndicate of banks (the “Credit Agreement”), matures on February 28, 2024. On March 1, 2023, the Company disclosed that during the First Quarter of 2023, it had breached the minimum liquidity covenant contained in the Credit Agreement. On June 29, 2023, the Company entered into a second amended and restated limited waiver and consent (the “Third Waiver”) under the Credit Agreement. The Third Waiver amended and restated the amended and restated limited waiver and consent entered into by the Company under the Credit Agreement on April 28, 2023 (the “Second Waiver”), which had amended and restated the limited waiver and consent entered into by the Company under the Credit Agreement on February 28, 2023 (the “Original Waiver”). The Third Waiver amended the Second Waiver and the Original Waiver by, among other things, extending the temporary waiver of compliance with the minimum liquidity covenant set forth in Section 11.12.2 of the Credit Agreement, which spanned from January 25, 2023 to June 30, 2023 under the Original Waiver and the Second Waiver, to January 25, 2023 to August 29, 2023 (the “Extended Waiver Period”). The Third Waiver also, among other things, added covenants (a) requiring the Company to deliver by July 17, 2023, an agreed term sheet for an equity or debt financing (the “Bridge Financing”) to support the Company’s ongoing operating cash needs through December 31, 2023 and, by July 31, 2023 (extended to August 4, 2023), definitive documentation for the Bridge Financing and an updated budget of the Company, (b) prohibiting the incurrence of certain types of debt and (c) requiring the Company not to request any interest period for any term SOFR borrowing other than a one-month interest period. On August 4, 2023, the Company entered into a Credit Agreement (as amended, supplemented, restated or otherwise modified from time to time, the “New Credit Agreement”), among the Company, NEA 18 Venture Growth Equity, L.P. (“NEA”) and the lenders from time to time party thereto (together with NEA and each of their respective successors and assigns, the “Lenders”), to provide for a credit facility pursuant to which, among other things, the lenders have provided $60.0 million delayed draw term loan commitments. The Company may borrow delayed draw term loans under such commitments at any time and from time to time on or prior to the date that is nine months after the effective date of the New Credit Agreement, subject to the satisfaction or waiver of customary conditions. Borrowings under the New Credit Agreement accrue interest at a rate per annum of 15.00%, payable quarterly in arrears at the Company’s election, subject to limitations set forth in the Fourth Waiver (defined below) in respect of cash payments under the New Credit Agreement, either in cash or “in kind” by adding the amount of accrued interest to the principal amount of the outstanding loans under the New Credit Agreement. The New Credit Agreement contains covenants that, among other things, restrict the ability of the Company and its subsidiaries to make certain restricted payments, incur additional debt, engage in certain asset sales, mergers, acquisitions or similar transactions, create liens on assets, engage in certain transactions with affiliates, change its business or make investments. The New Credit Agreement constitutes the Bridge Financing referred to in the Third Waiver. On August 4, 2023, the Company entered into a third amended and restated limited waiver and consent (the “Fourth Waiver”) under the Credit Agreement. The Fourth Waiver amends and restates the Third Waiver by, among other things, permanently waiving compliance with the minimum liquidity covenant set forth in Section 11.12.2 of the Credit Agreement, which waiver under the Third Waiver previously was temporary and would have expired on August 29, 2023. From August 4, 2023 until the Credit Agreement is terminated and all outstanding loans thereunder are repaid, the Company will be subject to a minimum liquidity covenant of not less than $25.0 million. The Fourth Waiver also, among other things, (a) removes from the credit agreement in its entirety the covenant requiring maintenance of a maximum total debt to capitalization ratio, which absent such removal would have applied after September 30, 2023, (b) prohibits the incurrence of certain types of debt and (c) requires the Company not to request any interest period for any Term Benchmark borrowing other than a one-month interest period. In connection with the New Credit Agreement, on August 4, 2023, the Company and the Lenders entered into a warrantholders agreement (the “Warrantholders Agreement”) setting forth the rights and obligations of the Company and the Lenders as holders (in such capacity, the “Holders”) of the warrants to acquire shares of Common Stock at an exercise price of $0.01 per share (the “Warrants”), and providing for the issuance of the Warrants to purchase up to 1,656,789 shares of the Company’s common stock. Any future non-compliance with the covenants under the Credit Agreement or the Fourth Waiver, or termination of our agreement to sell our Medicare Advantage business in California to Molina Healthcare, Inc. (“the Molina Purchase Agreement”), may result in the obligations under the Credit Agreement being accelerated. Based on our projected cash flows and absent any other action, the Company may not meet certain covenants under the Credit Agreement, the Fourth Waiver or the New Credit Agreement which may result in the obligations under the Credit Agreement and New Credit Agreement being accelerated. The Company will require additional liquidity to meet its obligations as they come due in the 12 months following the date the condensed consolidated financial statements contained in this Quarterly Report are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In response to these conditions, management has implemented a restructuring plan to reduce capital needs and our operating expenses in the future to drive positive operating cash flow and increase liquidity. The Company’s Bright HealthCare - Commercial business exited the ACA marketplace at the end of the 2022 plan year. In addition to our market exits, management is in the process of executing upon additional restructuring activities, which include reducing our workforce, exiting excess office space, and terminating or restructuring contracts. The Company closed on a $175.0 million capital raise in October 2022 to fund our continuing operations as further described in Note 7, Redeemable Convertible Preferred Stock . On June 30, 2023, the Company entered into the Molina Purchase Agreement to sell its California Medicare Advantage business, which consists of Brand New Day and Central Health Plan, for total purchase consideration of $600.0 million, subject to regulatory approval and other closing conditions. The closing of this transaction is expected to occur by early 2024. Further, as described above, the Company entered into the New Credit Agreement on August 4, 2023. In the event the Company is unable to execute the sale of the California Medicare Advantage business, obtain additional financing or take other management actions, among other potential consequences, we forecast we will be unable to satisfy our obligations. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Reverse Stock Split: During our annual meeting on May 4, 2023, our stockholders voted to approve an amendment to our Ninth Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio of not less than 1-for-15 and not greater than 1-for-80, with the exact ratio and effective time of the Reverse Stock Split to be determined by our Board of Directors at any time within one year of the date of the Annual Meeting. On May 5, 2023, our Board approved a ratio of 1-for-80. The reverse stock split took effect on May 19, 2023. The reverse stock split decreased the number of outstanding shares of the Company’s common stock by a factor of 80, subject to rounding of shares. The reverse stock split did not affect any stockholder’s proportionate equity interest in the Company. The par value of the Company’s common stock remains at $0.0001 per share following the reverse stock split and the number of outstanding shares of the Company’s common stock was proportionally reduced. As a consequence, the aggregate par value of the Company’s outstanding common stock was reduced, while the aggregate capital in excess of par value attributable to the Company’s outstanding common stock for accounting purposes was correspondingly increased. Total stockholder equity was not affected. All shares and per share information has been retroactively adjusted following the effective date of the reverse stock split to reflect the reverse stock split for all periods presented in future filings. Operating Costs: Our operating costs, by functional classification for the three and six months ended June 30, 2023 and 2022, are as follows (in thousand s) : Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Compensation and fringe benefits $ 42,413 $ 55,497 $ 101,037 $ 125,008 Professional fees 13,771 6,962 19,619 15,745 Marketing and selling expenses 630 842 1,204 2,270 General and administrative expenses 7,766 5,999 15,223 13,917 Other operating expenses 5,700 9,697 12,715 18,845 Total operating costs $ 70,280 $ 78,997 $ 149,798 $ 175,785 Recently Issued and Adopted Accounting Pronouncements: There are no accounting pronouncements that were recently issued and not yet adopted or adopted since our audited consolidated financial statements were issued that had, or are expected to have, a material impact on our consolidated financial position, results of operations, or cash flows. Correction of prior period financial statements: As previously reported, subsequent to the issuance of the condensed consolidated financial statements for the quarter ended June 30, 2022, we identified an error in the accounting for gross versus net revenue recognition conclusion from certain value-based care arrangements. As a result, Capitated revenue and Medical costs have been reduced by $54.9 million and $113.2 million for the three and six months ended June 30, 2022, respectively. There is no impact on Operating loss or Net loss. There was no impact to the condensed consolidated balance sheets, condensed consolidated statements of comprehensive income (loss), condensed consolidated statements of changes in redeemable preferred stock and shareholders’ equity (deficit) and condensed consolidated statements of cash flows. The Company determined that the correction of these errors was not material to the condensed consolidated financial statements.

RESTRUCTURING CHARGES

RESTRUCTURING CHARGES	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
RESTRUCTURING CHARGES	RESTRUCTURING CHARGES In October 2022, we announced our decision to further focus our business on our Fully Aligned Care Model, and that we will no longer offer commercial plans through Bright HealthCare, or Medicare Advantage products outside of California in 2023. As a result of these strategic changes, we announced and have taken actions to restructure the Company’s workforce and reduce expenses based on our updated business model. Restructuring charges by reportable segment and corporate for the periods ended June 30 were as follows (in thousands) : Three Months Ended June 30, 2023 Care Delivery Care Solutions Corporate & Eliminations Total Employee termination benefits $ — $ — $ 1,387 $ 1,387 Long-lived asset impairments — — — — Contract termination and other costs — — (102) (102) Total continuing operations $ — $ — $ 1,285 $ 1,285 Three Months Ended June 30, 2022 Care Delivery Care Solutions Corporate & Eliminations Total Employee termination benefits $ — $ — $ 2,604 $ 2,604 Long-lived asset impairments — — — — Contract termination and other costs — — 189 189 Total continuing operations $ — $ — $ 2,793 $ 2,793 Six Months Ended June 30, 2023 Care Delivery Care Solutions Corporate & Eliminations Total Employee termination benefits $ (44) $ 3 $ 662 $ 621 Long-lived asset impairments — — 880 880 Contract termination and other costs — — 85 85 Total continuing operations $ (44) $ 3 $ 1,627 $ 1,586 Six Months Ended June 30, 2022 Care Delivery Care Solutions Corporate & Eliminations Total Employee termination benefits $ — $ — $ 8,701 $ 8,701 Long-lived asset impairments — — — — Contract termination and other costs — — 956 956 Total continuing operations $ — $ — $ 9,657 $ 9,657 The $0.9 million of long-lived asset impairments is the result of a lease abandonment for one of our corporate office locations during the six months ended June 30, 2023 . Restructuring accrual activity recorded by major type for the six months ended June 30, 2023 were as follows (in thousands) : Employee Termination Benefits Contract Termination Costs Total Balance at January 1, 2023 $ 24,077 $ — $ 24,077 Charges 621 85 706 Cash payments (16,935) (85) (17,020) Balance at June 30, 2023 $ 7,763 $ — $ 7,763 Employee termination benefits are recorded within Other current liabilities while contract termination costs are recorded within Accounts payable.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Changes in the carrying value of goodwill by reportable segment were as follows (in thousands) : June 30, 2023 December 31, 2022 Gross Carrying Cumulative Gross Carrying Cumulative Care Delivery $ 401,385 $ — $ 401,385 $ — Total $ 401,385 $ — $ 401,385 $ — For the periods ending June 30, 2023 and December 31, 2022, Care Solutions had no assigned goodwill. The gross carrying value and accumulated amortization for definite-lived intangible assets were as follows (in thousand s) : June 30, 2023 December 31, 2022 Gross Carrying Accumulated Amortization Gross Carrying Accumulated Amortization Customer relationships $ 80,021 $ 21,910 $ 80,021 $ 17,655 Trade names 48,361 7,388 48,361 5,776 Total $ 128,382 $ 29,298 $ 128,382 $ 23,431 There was no impairment expense for the three and six months ended June 30, 2023 and 2022. We are continuously evaluating factors that affect the fair values of our reporting units including our market capitalization, macroeconomic trends and other events and uncertainties. Negative trends in these factors could result in a non-cash charge for impairment to goodwill or intangible assets in a future period. Amortization expense relating to intangible assets for the three months ended June 30, 2023 and 2022 was $2.9 million and $6.2 million, respectively and amortization expense for the six months ended June 30, 2023 and 2022 was $5.9 million and $12.4 million, respectively. Estimated amortization expense relating to intangible assets for the remainder of 2023 and for each of the next five full years ending December 31 is as follows (in thousand s) : 2023 (July-December) $ 5,846 2024 $ 11,574 2025 $ 11,574 2026 $ 11,574 2027 $ 11,574 2028 $ 10,295

MEDICAL COSTS PAYABLE

MEDICAL COSTS PAYABLE	6 Months Ended
	Jun. 30, 2023
Insurance [Abstract]
MEDICAL COSTS PAYABLE	MEDICAL COSTS PAYABLE The following table shows the components of the change in medical costs payable for the six months ended June 30 (in thousand s) : June 30, 2023 2022 Medical costs payable - January 1 $ 116,021 $ 6,764 Incurred related to: Current year 504,307 312,339 Prior year 1,029 (2,089) Total incurred 505,336 310,250 Paid related to: Current year 347,629 210,452 Prior year 93,873 4,547 Total paid 441,502 214,999 Medical costs payable - June 30 $ 179,855 $ 102,015 Medical costs payable attributable to prior years increased by $1.0 million and decreased by $2.1 million for the six months ended June 30, 2023 and 2022, respectively. Medical costs payable estimates are adjusted as additional information regarding claims becomes known; there were no significant changes to estimation methodologies during the periods. The table below details the components making up the medical costs payable as of June 30 (in thousand s) : June 30, 2023 2022 Provider incentive payable $ 27,884 $ — Incurred but not reported (IBNR) 151,971 102,015 Total medical costs payable $ 179,855 $ 102,015 Medical costs payable are primarily related to the current year. The Company has recorded claims adjustment expense as a component of operating costs in the Condensed Consolidated Statements of Income (Loss).

SHORT-TERM BORROWINGS

SHORT-TERM BORROWINGS	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
SHORT-TERM BORROWINGS	SHORT-TERM BORROWINGS We have a $350.0 million revolving credit agreement with a syndicate of banks (the “Credit Agreement”), which matures on February 28, 2024. As of June 30, 2023 and December 31, 2022 we had $303.9 million borrowed under the Credit Agreement at a weighted-average effective annual interest rate of 10.19%, which remains outstanding as of June 30, 2023. Refer to Note 9, Commitments and Contingencies for more information on the undrawn letters of credit of $30.7 million under the Credit Agreement, which reduce the amount available to borrow. On June 29, 2023, the Company entered into a second amended and restated limited waiver and consent (the “Third Waiver”) under the Credit Agreement, which amended and restated the amended and restated limited waiver and consent entered into by the Company under the Credit Agreement on April 28, 2023 (the “Second Waiver”), which previously amended and restated that certain limited waiver and consent entered into by the Company under the Credit Agreement on February 28, 2023 (the “Original Waiver”). The Third Waiver amended the Second Waiver and the Original Waiver by, among other things, extending the temporary waiver of compliance with the minimum liquidity covenant set forth in Section 11.12.2 of the Credit Agreement, which spanned from January 25, 2023 to June 30, 2023 under the Original Waiver and the Existing Waiver, to January 25, 2023 to August 29, 2023 (the “Extended Waiver Period”). The Third Waiver also, among other things, added covenants (a) requiring the Company to deliver by July 17, 2023, an agreed term sheet for the Bridge Financing to support the Company’s ongoing operating cash needs through December 31, 2023 and, by July 31, 2023 (extended to August 4, 2023), definitive documentation for the Bridge Financing and an updated budget of the Company, (b) prohibiting the incurrence of certain types of debt and (c) requiring the Company not to request any interest period for any term SOFR borrowing other than a one-month interest period. On August 4, 2023, the Company entered into a Credit Agreement (as amended, supplemented, restated or otherwise modified from time to time, the “New Credit Agreement”), among the Company, NEA 18 Venture Growth Equity, L.P. (“NEA”) and the lenders from time to time party thereto (together with NEA and each of their respective successors and assigns, the “Lenders”), to provide for a credit facility pursuant to which, among other things, the lenders have provided $60.0 million delayed draw term loan commitments. The Company may borrow delayed draw term loans under such commitments at any time and from time to time on or prior to the date that is nine months after the effective date of the New Credit Agreement, subject to the satisfaction or waiver of customary conditions. Borrowings under the New Credit Agreement accrue interest at a rate per annum of 15.00%, payable quarterly in arrears at the Company’s election, subject to limitations set forth in the Fourth Waiver (defined below) in respect of cash payments under the New Credit Agreement, either in cash or “in kind” by adding the amount of accrued interest to the principal amount of the outstanding loans under the New Credit Agreement. The New Credit Agreement contains covenants that, among other things, restrict the ability of the Company and its subsidiaries to make certain restricted payments, incur additional debt, engage in certain asset sales, mergers, acquisitions or similar transactions, create liens on assets, engage in certain transactions with affiliates, change its business or make investments. The New Credit Agreement constitutes the Bridge Financing referred to in the Third Waiver. On August 4, 2023, the Company entered into a third amended and restated limited waiver and consent (the “Fourth Waiver”) under the Credit Agreement. The Fourth Waiver amends and restates the Third Waiver by, among other things, permanently waiving compliance with the minimum liquidity covenant set forth in Section 11.12.2 of the Credit Agreement, which under the Third Waiver previously was temporary and would have expired on August 29, 2023. From August 4, 2023 until the Credit Agreement is terminated and all outstanding loans thereunder are repaid, the Company will be subject to a minimum liquidity covenant of not less than $25.0 million. The Fourth Waiver also, among other things, (a) removes from the credit agreement in its entirety the covenant requiring maintenance of a maximum total debt to capitalization ratio, which absent such removal would have applied after September 30, 2023, (b) prohibits the incurrence of certain types of debt and (c) requires the Company not to request any interest period for any Term Benchmark borrowing other than a one-month interest period.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION 2016 Incentive Plan The Company adopted its 2016 Stock Incentive Plan (the “2016 Incentive Plan”) in March 2016. The 2016 Incentive Plan allowed for the Company to grant stock options, restricted stock awards (“RSAs”), and restricted stock units (“RSUs”) to certain employees, consultants and non-employee directors. The 2016 Incentive Plan was initially adopted on March 25, 2016, and most recently amended in December 2020. Following the effectiveness of our 2021 Omnibus Plan (the “2021 Incentive Plan”), no further awards will be granted under the 2016 Incentive Plan. However, all outstanding awards granted under the 2016 Incentive Plan will continue to be governed by the existing terms of the 2016 Incentive Plan and the applicable award agreements. 2021 Incentive Plan The 2021 Incentive Plan was adopted by our Board of Directors on May 21, 2021 and approved by our stockholders on May 25, 2021 and June 5, 2021. The 2021 Incentive Plan allows the Company to grant stock options, RSAs, RSUs, stock appreciation rights, other equity based awards, and cash based incentive awards to certain employees, consultants and non-employee directors. There are 1.7 million shares of common stock authorized for issuance under the 2021 Incentive Plan. As of June 30, 2023, a total of 0.3 million shares of common stock were available for future issuance under the 2021 Incentive Plan. Share-Based Compensation Expense We recognized share-based compensation expense of $49.1 million and $53.1 million for the six months ended June 30, 2023 and 2022, respectively, which is included in operating costs in the Condensed Consolidated Statements of Income (Loss). Stock Options The Board of Directors, or the Compensation and Human Capital Committee of the Board of Directors, as applicable, determines the exercise price, vesting periods and expiration date at the time of the grant. Stock options granted prior to the third quarter of 2021 generally vest 25% at one year from the grant date, then ratably over the next 36 months with continuous employee service. Stock options granted after the beginning of the third quarter of 2021 generally vest ratably over three years. Option grants generally expire 10 years from the date of grant. There were no options granted during the six months ended June 30, 2023. The activity for stock options for the six months ended June 30, 2023 is as follows (in thousand s, except exercise price and contractual life) : Shares Weighted-Average Weighted-Average Aggregate Outstanding at January 1, 2023 804 $ 145.60 6.7 $ 6,560 Granted — — Exercised — — Forfeited (26) 220.21 Expired (58) 151.36 Outstanding at June 30, 2023 720 $ 142.13 5.2 $ 569 We recognized share-based compensation expense related to stock options of $24.5 million for the six months ended June 30, 2023, which is included in operating costs in the Condensed Consolidated Statements of Income (Loss). At June 30, 2023, there was $17.7 million of unrecognized compensation expense related to stock options that is expected to be recognized over a weighted-average period of 1.6 years. Restricted Stock Units RSUs represent the right to receive shares of our common stock at a specified date in the future and generally vest over a three-year period, except for Board of Director grants which generally vest one year from the date of grant. The fair value of RSUs is determined based on the closing market price of our common stock on the date of grant. The following table summarizes RSU award activity for the six months ended June 30, 2023 (in thousand s, except weighted average grant date fair value) : Number of RSUs Weighted Average Grant Date Fair Value Unvested RSUs at December 31, 2022 470 $ 189.88 Granted 964 32.24 Vested (94) 129.70 Forfeited (232) 101.45 Unvested RSUs at June 30, 2023 1,108 $ 72.57 We recognized share-based compensation expense related to RSUs of $10.8 million for the six months ended June 30, 2023, which is included in operating costs in the Condensed Consolidated Statements of Income (Loss). As of June 30, 2023, there was $44.3 million of unrecognized compensation expense related to the RSU grants, which is expected to be recognized over a weighted-average period of 1.8 years. Performance-based Restricted Stock Units (“PSUs”) In connection with our IPO, our Board of Directors approved the grant of PSUs to members of our executive leadership team. The grant encompassed a total of 183,750 PSUs, separated into four equal tranches, each of which are eligible to vest based on the achievement of predetermined stock price goals and a minimum service period of 3.0 years. The fair value of the PSUs was determined using a Monte-Carlo simulation. The following table summarizes PSU award activity for the six months ended June 30, 2023 (in thousand s, except weighted average grant date fair value) : Number of PSUs Weighted Average Grant Date Fair Value Unvested PSUs at December 31, 2022 131 $ 744.00 Granted — — Forfeited — — Unvested PSUs at June 30, 2023 131 $ 744.00

REDEEMABLE CONVERTIBLE PREFERRE

REDEEMABLE CONVERTIBLE PREFERRED STOCK	6 Months Ended
	Jun. 30, 2023
Temporary Equity Disclosure [Abstract]
REDEEMABLE CONVERTIBLE PREFERRED STOCK	REDEEMABLE CONVERTIBLE PREFERRED STOCK Series A Convertible Preferred Stock On January 3, 2022, we issued 750,000 shares of Series A Preferred Stock, par value $0.0001 per share, for an aggregate purchase price of $750.0 million, or $1,000 per share. The Series A Preferred Stock ranks senior to the shares of the Company’s common stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The Preferred Stock has an initial liquidation preference of $1,000 per share, which shall increase by accumulated quarterly dividends that are not paid in cash (“compounded dividends”). Holders of the Series A Preferred Stock are entitled to a dividend at the rate of 5.0% per annum, accruing daily and payable quarterly in arrears and subject to certain adjustments, as set forth in the Certificate of Designations. Dividends will be payable in cash, by increasing the amount of liquidation preference (compounded dividends) with respect to a share of Series A Preferred Stock, or any combination thereof, at the sole discretion of the Company. The Series A Preferred Stock had accrued compounded dividends of $57.6 million and $37.9 million as of June 30, 2023 and December 31, 2022, respectively. The Series A Preferred Stock will be convertible at the option of the holders into (I) the number of shares of common stock equal to the quotient of (a) the sum of (x) the liquidation preference (reflecting increases for compounded dividends) plus (y) the accrued dividends with respect to each share of Series A Preferred Stock as of the applicable conversion date divided by (b) the conversion price (initially approximately $364.00 per share and approximately $325.32 per share subsequent to the issuance of the Series B Preferred Stock) as of the applicable conversion date plus (II) cash in lieu of fractional shares, subject to certain anti‑dilution adjustments. At any time after January 3, 2025, if the closing price per share of Common Stock on the New York Stock Exchange was greater than 175% of the then effective Conversion Price for (x) each of at least twenty (20) trading days in any period of thirty (30) consecutive trading days and (y) the last trading day immediately before the Company provides the holders with notice of its election to convert all of the Series A Preferred Stock into the relevant number of shares of common stock, the Company may elect to convert all of the Series A Preferred Stock into the relevant number of shares of common stock. Under the Certificate of Designations, holders of the Series A Preferred Stock are entitled to vote with the holders of the common stock on an as‑converted basis, solely with respect to (i) a change of control transaction (to the extent such change of control transaction is submitted to a vote of the holders of the common stock) or (ii) the issuance of capital stock by the Company in connection with an acquisition by the Company (to the extent such issuance is submitted to a vote of the holders of the common stock), subject to certain restrictions. Holders of the Series A Preferred Stock are entitled to a separate class vote with respect to, among other things, amendments to the Company’s organizational documents that have an adverse effect on the Series A Preferred Stock, authorizations or issuances by the Company of securities that are senior to the Series A Preferred Stock, increases or decreases in the number of authorized shares of Preferred Stock, and issuances of shares of the Series A Preferred Stock after January 3, 2022. At any time following January 3, 2027, the Company may redeem all of the Series A Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to January 3, 2029 and (B) 100% if the redemption occurs at any time on or after January 3, 2029. Upon certain change of control events involving the Company, the holders of the Series A Preferred Stock may, at such holder’s election, convert their shares of Series A Preferred Stock into common stock at the then‑current conversion price or require the Company to purchase all or a portion of such holder’s shares of Preferred Stock that have not been so converted at a purchase price per share of Preferred Stock, payable in cash, equal to the greater of (I) (A) if the change of control effective date occurs at any time prior to January 3, 2029, the product of 105% multiplied by the sum of (x) the liquidation preference of such share of Series A Preferred Stock (reflecting increases for compounded dividends) plus (y) the accrued dividends in respect of such share of Series A Preferred Stock as of the change of control purchase date and (B) if the change of control effective date occurs on or after January 3, 2029, the sum of (x) the liquidation preference (reflecting increases for compounded dividends) of such share of Series A Preferred Stock plus (y) the accrued dividends in respect of such share of Series A Preferred Stock as of the change of control purchase date and (II) the consideration that would have been payable in connection with such change of control if such share of Series A Preferred Stock had been converted into Common Stock immediately prior to the change of control. Series B Convertible Preferred Stock On October 17, 2022, we issued 175,000 shares of Series B Preferred Stock, par value $0.0001 per share, for an aggregate purchase price of $175.0 million, or $1,000 per share. The Series B Preferred Stock ranks senior to the shares of the Company’s common stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The Preferred Stock has an initial liquidation preference of $1,000 per share, which shall increase by compounded dividends. Holders of the Series B Preferred Stock are entitled to a dividend at the rate of 5.0% per annum, accruing daily and payable quarterly in arrears and subject to certain adjustments, as set forth in the Certificate of Designations. Dividends will be payable in cash, by increasing the amount of liquidation preference (compounded dividends) with respect to a share of Series B Preferred Stock, or any combination thereof, at the sole discretion of the Company. The Series B Preferred Stock had accrued compounded dividends of $6.2 million and $1.8 million as of June 30, 2023 and December 31, 2022, respectively. The Series B Preferred Stock will be convertible at the option of the holders into (I) the number of shares of common stock equal to the quotient of (a) the sum of (x) the liquidation preference (reflecting increases for compounded dividends) plus (y) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price (initially approximately $113.60 per share) as of the applicable conversion date plus (II) cash in lieu of fractional shares, subject to certain anti‑dilution adjustments. At any time after October 17, 2025, if the closing price per share of common stock on the NYSE was greater than 287% of the then effective Conversion Price for (x) each of at least twenty (20) trading days in any period of thirty (30) consecutive trading days and (y) the last trading day immediately before the Company provides the holders with notice of its election to convert all of the Series B Preferred Stock into the relevant number of shares of common stock, the Company may elect to convert all of the Series B Preferred Stock into the relevant number of shares of common stock. Under the Certificate of Designations, holders of the Series B Preferred Stock are entitled to vote with the holders of the common stock on an as‑converted basis, solely with respect to (i) a change of control transaction (to the extent such change of control transaction is submitted to a vote of the holders of the common stock) or (ii) the issuance of capital stock by the Company in connection with an acquisition by the Company (to the extent such issuance is submitted to a vote of the holders of the common stock), subject to certain restrictions. Holders of the Series B Preferred Stock are entitled to a separate class vote with respect to, among other things, amendments to the Company’s organizational documents that have an adverse effect on the Series B Preferred Stock, authorizations or issuances by the Company of securities that are senior to the Series B Preferred Stock, increases or decreases in the number of authorized shares of Preferred Stock, and issuances of shares of the Series B Preferred Stock after October 17, 2022. At any time following October 17, 2027, the Company may redeem all of the Series B Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to October 17, 2029 and (B) 100% if the redemption occurs at any time on or after October 17, 2029. Upon certain change of control events involving the Company, the holders of the Series B Preferred Stock may, at such holder’s election, convert their shares of Series B Preferred Stock into common stock at the then‑current conversion price or require the Company to purchase all or a portion of such holder’s shares of Preferred Stock that have not been so converted at a purchase price per share of Preferred Stock, payable in cash, equal to the greater of (I) (A) if the change of control effective date occurs at any time prior to October 17, 2029, the product of 105% multiplied by the sum of (x) the liquidation preference of such share of Series B Preferred Stock (reflecting increases for compounded dividends) plus (y) the accrued dividends in respect of such share of Series B Preferred Stock as of the change of control purchase date and (B) if the change of control effective date occurs on or after October 17, 2029, the sum of (x) the liquidation preference (reflecting increases for compounded dividends) of such share of Series B Preferred Stock plus (y) the accrued dividends in respect of such share of Series B Preferred Stock as of the change of control purchase date and (II) the consideration that would have been payable in connection with such change of control if such share of Series B Preferred Stock had been converted into common stock immediately prior to the change of control.

NET LOSS PER SHARE

NET LOSS PER SHARE	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
NET LOSS PER SHARE	NET LOSS PER SHARE The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the three and six months ended June 30 (in thousand s, except for per share amounts) : Three Months Ended Six Months Ended 2023 2022 2023 2022 Loss from continuing operations, net noncontrolling interests and accrued preferred stock dividends $ (68,070) $ (107,559) $ (139,432) $ (252,680) Loss from discontinued operations (56,935) (176,568) (172,478) (235,619) Net loss attributable to Bright Health Group, Inc. common shareholders $ (125,005) $ (284,127) $ (311,910) $ (488,299) Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted 7,962 7,865 7,928 7,862 Basic and diluted loss per share attributable to Bright Health Group, Inc. common shareholders Continuing operations $ (8.55) $ (13.68) $ (17.59) $ (32.14) Discontinued operations $ (7.15) $ (22.45) $ (21.76) $ (29.97) Net loss per share attributable to common stockholders, basic and diluted $ (15.70) $ (36.13) $ (39.35) $ (62.11) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive effect for the six months ended June 30 (in thousand s) : Six Months Ended 2023 2022 Redeemable convertible preferred stock (as converted to common stock) 4,081 2,112 Stock options to purchase common stock 720 853 Restricted stock units 1,108 458 Total 5,909 3,423

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal proceedings: In the normal course of business, we could be involved in various legal proceedings such as, but not limited to, the following: lawsuits alleging negligence in care or general liability, violation of regulatory bodies’ rules and regulations, or violation of federal and/or state laws. On January 6, 2022, a putative securities class action lawsuit was filed against us and certain of our officers and directors in the Eastern District of New York. The case is captioned Marquez v. Bright Health Group, Inc. et al., 1:22-cv-00101 (E.D.N.Y.). The lawsuit alleges, among other things, that we made materially false and misleading statements regarding our business, operations, and compliance policies, which in turn adversely affected our stock price. An amended complaint was filed on June 24, 2022, which expands on the allegations in the original complaint and alleges a putative class period of June 24, 2021 through March 1, 2022. The amended complaint also adds as defendants the underwriters of our initial public offering. The Company has served a motion to dismiss the amended complaint, which has not yet been ruled on by the court. We are vigorously defending the Company in the above actions, but there can be no assurance that we will be successful in any defense. Based on our assessment of the facts underlying the claims and the degree to which we intend to defend the Company in these matters, other than as set forth above, the amount or range of reasonably possible losses, if any, cannot be estimated. We have not accrued for any potential loss as of June 30, 2023 and December 31, 2022 for these actions.

SEGMENTS AND GEOGRAPHIC INFORMA

SEGMENTS AND GEOGRAPHIC INFORMATION	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
SEGMENTS AND GEOGRAPHIC INFORMATION	SEGMENTS AND GEOGRAPHIC INFORMATION Factors used to determine our reportable segments include the nature of operating activities, economic characteristics, existence of separate senior management teams and the type of information used by the Company’s CODM to evaluate its results of operations. We have identified two operating segments within our continuing operations based on our primary product and service offerings: Care Delivery and Care Solutions. The Care Delivery and Care Solutions segments are new in the second quarter of 2023 and were formerly reported together within the aggregated Consumer Care segment. The updates to our reportable segments conform with the Company’s CODM’s view of our ongoing operations. Care Delivery and Care Solutions, which make up o ur value-driven Consumer Care business that manages risk in partnership with external payors, aim to significantly reduce the friction and current lack of coordination between payors by delivering on our Fully-Aligned Care Model with multiple payors. The following is a description of the types of products and services from which the two reportable segments of our continuing operations derive their revenues: Care Delivery: Provides care services in our clinics with wrap around care management and care coordination activities for those members where we take full or partial risk. As of June 30, 2023, Care Delivery provides virtual and in-person clinical care through its 71 owned primary care clinics within an integrated care delivery system. Through these risk-bearing clinics and our affiliated network of care providers, our Care Delivery segment serves approximately 340,000 consumers. Care Delivery customers include external payors, third party administrators, affiliated providers and direct-to-government programs. Care Solutions: Our provider enablement business that facilitates care coordination activities through the use of population health tools including technology, data analytics, care and utilization management, and clinical solutions and care teams to support patients. As of June 30, 2023, Care Solutions has approximately 65,000 members attributed to its REACH ACO’s. The Company’s accounting policies for reportable segment operations are consistent with those described in Note 2, Summary of Significant Accounting Policies, in our 2022 Form 10-K. We utilize operating income (loss) before income taxes as the profitability metric for our reportable segments. The following tables present the reportable segment financial information for the three and six months ended June 30, 2023 and 2022 (in thousand s) : Three Months Ended June 30, 2023 Care Delivery Care Solutions Corporate & Eliminations Consolidated Capitated revenue $ 49,764 $ — $ — $ 49,764 ACO REACH revenue — 236,994 — 236,994 Service revenue 10,530 692 — 11,222 Investment income (loss) — — 2 2 Total unaffiliated revenue 60,294 237,686 2 297,982 Affiliated revenue 5,774 — (5,774) — Total segment revenue 66,068 237,686 (5,772) 297,982 Operating income (loss) 11,031 2,996 (37,441) (23,414) Depreciation and amortization 3,178 — 1,493 4,671 Restructuring charges — — 1,285 1,285 Three Months Ended June 30, 2022 Care Delivery Care Solutions Corporate & Eliminations Consolidated Capitated revenue $ 17,641 $ — $ — $ 17,641 ACO REACH revenue — 137,205 — 137,205 Service revenue 10,691 41 — 10,732 Investment income (loss) — — (16,238) (16,238) Total unaffiliated revenue 28,332 137,246 (16,238) 149,340 Affiliated revenue 204,271 — (204,271) — Total segment revenue 232,603 137,246 (220,509) 149,340 Operating income (loss) (698) 825 (71,646) (71,519) Depreciation and amortization 6,369 — 1,907 8,276 Restructuring charges — — 2,793 2,793 Six Months Ended June 30, 2023 Care Delivery Care Solutions Corporate & Eliminations Consolidated Capitated revenue $ 99,312 $ — $ — $ 99,312 ACO REACH revenue — 476,801 — 476,801 Service revenue 21,466 943 — 22,409 Investment income (loss) — — 10 10 Total unaffiliated revenue 120,778 477,744 10 598,532 Affiliated revenue 7,969 — (7,969) — Total segment revenue 128,747 477,744 (7,959) 598,532 Operating income (loss) 17,667 1,487 (87,440) (68,286) Depreciation and amortization 6,310 — 3,844 10,154 Restructuring charges — — 1,586 1,586 Six Months Ended June 30, 2022 Care Delivery Care Solutions Corporate & Eliminations Consolidated Capitated revenue $ 46,289 $ — $ — $ 46,289 ACO REACH revenue — 320,002 — 320,002 Service revenue 20,910 52 — 20,962 Investment income (loss) — — (57,149) (57,149) Total unaffiliated revenue 67,199 320,054 (57,149) 330,104 Affiliated revenue 572,391 — (572,391) — Total segment revenue 639,590 320,054 (629,540) 330,104 Operating income (loss) (22,749) 4,989 (164,163) (181,923) Depreciation and amortization 12,745 — 3,591 16,336 Restructuring charges — — 9,657 9,657

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXESIncome tax was a benefit of $0.9 million and an expense of $2.9 million for the three months ended June 30, 2023 and 2022, respectively. For the six months ended June 30, 2023 and 2022, income tax was an expense of $0.4 million and $12.9 million, respectively. The impact from income taxes varies from the federal statutory rate of 21.0% due to state income taxes, changes in the valuation allowance for deferred tax assets and adjustments for permanent differences. For the three and six months ended June 30, 2023, and 2022, the expense largely relates to amortization of originating goodwill from asset acquisitions and estimated state income taxes attributable to income earned in separate filing states without state net operating loss carryforwards.We assess whether sufficient future taxable income will be generated to permit the use of deferred tax assets. This assessment includes consideration of the cumulative losses incurred over the three-year period ended June 30, 2023. Such objective evidence limits the ability to consider other subjective evidence, such as the Company’s projections for future earnings. On the basis of this evaluation, we have recorded a valuation allowance for deferred tax assets to the extent that they cannot be supported by reversals of existing cumulative temporary differences. Any federal tax benefit generated from losses in 2023 is expected to require an offsetting adjustment to the valuation allowance for deferred tax assets, and thus have no net effect on the income tax provision.

REDEEMABLE NONCONTROLLING INTER

REDEEMABLE NONCONTROLLING INTEREST	6 Months Ended
	Jun. 30, 2023
Noncontrolling Interest [Abstract]
REDEEMABLE NONCONTROLLING INTEREST	REDEEMABLE NONCONTROLLING INTEREST Redeemable noncontrolling interests in our subsidiaries whose redemption is outside of our control are classified as temporary equity. The following table provides details of our redeemable noncontrolling interest activity for the three and six months e nded June 30, 2023 and 2022 (in thousand s) : 2023 2022 Balance at January 1 $ 219,758 $ 128,407 Earnings attributable to noncontrolling interest 1,421 (2,681) Distribution to noncontrolling interest holders (1,805) — Measurement adjustment 4,129 17,285 Balance at March 31 $ 223,503 $ 143,011 Earnings attributable to noncontrolling interest 3,139 3,625 Distribution to noncontrolling interest holders (3,147) (1,894) Measurement adjustment 21,066 19,712 Balance at June 30 $ 244,561 $ 164,454

ACO REACH

ACO REACH	6 Months Ended
	Jun. 30, 2023
Direct Contracting [Abstract]
ACO REACH	ACO REACH We participate in the Centers for Medicare & Medicaid Services’ (“CMS”) ACO REACH Model with three REACH ACOs participating through the global risk arrangement and assuming full risk for the total cost of care of aligned beneficiaries. As part of our participation in the ACO REACH Model, we are guaranteeing the performance of our care network of participating and preferred providers. The intention of the ACO REACH Model is to enhance the quality of care for Medicare FFS beneficiaries while reducing the administrative burden, supporting a focus on complex, chronically ill patients, and encouraging physician organizations that have not typically participated in Medicare FFS programs to serve Medicare FFS beneficiaries. Key components of the financial agreement for the ACO REACH Model include: • Performance Year Benchmark: The target amount for Medicare expenditures on covered services (Medicare Part A and B) furnished to a REACH ACO’s aligned beneficiaries during a performance year. The Performance Year Benchmark will be compared to the REACH ACO’s performance year expenditures. This comparison will be used to calculate shared savings and shared losses. The Performance Year Benchmark is established at the beginning of the performance year utilizing prospective trend estimates and is subject to retrospective trend adjustments, if warranted, before the Financial Reconciliation. • Risk-Sharing Arrangements: Used in determining the percent of savings and losses that REACH ACOs are eligible to receive as shared savings or may be required to repay as shared losses. • Financial Reconciliation: The process by which CMS determines shared savings or shared losses by comparing the calculated total benchmark expenditures for a given REACH ACO’s aligned population to the actual expenditures of that REACH ACO’s aligned beneficiaries over the course of a performance year that includes various risk-mitigation options such as stop-loss reinsurance and risk corridors. • Risk-Mitigation Options: Two of our REACH ACOs elected to participate in a “stop-loss arrangement” for the current and prior performance year offered by CMS, while one REACH ACO has elected third-party coverage. The “stop-loss arrangement” and third-party coverage are designed to reduce the financial uncertainty associated with high-cost expenditures of individual beneficiaries. Additionally, CMS has created a mandatory risk corridor program that allocates the REACH ACO’s shared savings and losses in bands of percentage thresholds, after a deviation of greater than 25.0% of the Performance Year Benchmark. Performance Guarantees Through our participation in the ACO REACH Model, we determined that our arrangements with the providers of our REACH ACO beneficiaries require us to guarantee their performance to CMS. At the beginning of the performance year, we recognized the ACO REACH estimated performance year obligation and receivable for the duration of the performance year. This receivable and obligation are measured at an amount equivalent to the estimated Performance Year Benchmark per CMS that is representative of the expected Medicare expenditures for beneficiaries aligned to our REACH ACOs. As we fulfill our obligation, we amortize the guarantee on a straight-line basis for the amount that represents the completed portion of the performance obligation. The receivable is reduced as we receive payments from CMS for in-network claims or receive CMS reporting detailing out-of-network claims paid by CMS on behalf of our aligned beneficiaries. At the end of each reporting period, we estimate both in-network claims and out-of-network claims incurred by beneficiaries aligned to our REACH ACOs but not yet reported and record a reserve for the estimated amount which is included in medical costs payable on the Condensed Consolidated Balance Sheets. For each performance year, the final consideration due to the REACH ACOs by CMS (shared savings) or the consideration due to CMS by the REACH ACOs (shared loss) is reconciled in the year following the performance year. On a quarterly basis CMS adjusts the estimated Performance Year Benchmark based upon revised trend assumptions and changes in attributed membership. CMS will also estimate the shared savings or loss for the REACH ACO on a quarterly basis based upon this revised estimated Performance Year Benchmark, changes to membership, payments made to the REACH ACO for in-network claims, out-of-network claims paid on behalf of the REACH ACO and various other assumptions including incurred but not reported reserves. The estimated Performance Year Benchmark is our best estimate of our obligation as we are unable to estimate the potential shared savings or loss due to the “stop-loss arrangement”, risk corridor components of the agreement, and a number of variables including but not limited to risk ratings and benchmark trends that could have an inestimable impact on estimated future payments. The tables below include the financial statement impacts of the performance guarantee at June 30, 2023 and for the three and six-month period then ended ( in thousands ): June 30, 2023 December 31, 2022 ACO REACH performance year receivable (1) $ 623,609 $ 99,181 ACO REACH performance year obligation 474,700 — (1) We estimate there to be $144.3 million and $1.2 million in-network and out-of-network claims incurred by beneficiaries aligned to our REACH ACOs but not reported as of June 30, 2023 and December 31, 2022, respectively; this is included in medical costs payable on the Condensed Consolidated Balance Sheets. Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Amortization of ACO REACH performance year receivable (1) $ 249,449 $ 156,808 $ 424,972 $ 231,935 Amortization of ACO REACH performance year obligation 234,893 164,404 474,700 347,201 ACO REACH revenue 236,994 137,205 476,801 320,002 (1) The amortization of the ACO REACH performance year receivable includes $99.2 million related to the amortization of the prior year receivable.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	6 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	DISCONTINUED OPERATIONSIn April 2023, we announced that we were exploring strategic alternatives for our California Medicare Advantage business, the Bright HealthCare reporting segment, with the focus on a potential sale. At this time, we met the criteria for “held for sale,” in accordance with ASC 205-20. This represents a strategic shift that will have a material impact on our business and financial results. As such, we have reflected amounts relating to Bright HealthCare as a disposal group as part of discontinued operations. On June 30, 2023, the Company entered into a definitive agreement with Molina Healthcare, Inc. to sell its California Medicare Advantage business, which consists of Brand New Day and Central Health Plan, for total purchase consideration of $600.0 million, subject to regulatory approval and other closing conditions. The closing of this transaction is expected to occur by early 2024. In October 2022, we announced that we will no longer offer commercial plans through our Bright HealthCare - Commercial segment in 2023. As a result, we exited the Commercial marketplace effective December 31, 2022. We determined this exit represented a strategic shift that will have a material impact on our business and financial results that requires presentation as discontinued operations. While we are no longer offering plans in the Commercial marketplace as of December 31, 2022, we will continue to have involvement in the states where we formerly operated in as we support run out activities of medical claims incurred in the 2022 plan year and perform other activities necessary to wind down our operations in each state, including making final payments of 2022 risk adjustment payable liabilities during the third quarter of 2023. We expect these activities to be substantially complete by the end of 2023. Our discontinued operations are also inclusive of our DocSquad business that was sold in March 2023; this is presented within the column labeled Other in the tables below. The discontinued operations presentation has been retrospectively applied to all prior periods presented. The financial results of discontinued operations by major line item for the periods ended June 30 were as follows (in thousands) : Three Months Ended June 30, 2023 Bright HealthCare - Commercial Bright HealthCare Other Total Revenue: Premium revenue $ (15,354) $ 443,532 $ — $ 428,178 Service revenue — — — — Investment income (loss) 21,120 400 — 21,520 Total revenue from discontinued operations 5,766 443,932 — 449,698 Operating expenses: Medical costs 14,588 400,114 — 414,702 Operating costs 35,859 54,289 318 90,466 Depreciation and amortization — 1,465 — 1,465 Total operating expenses from discontinued operations 50,447 455,868 318 506,633 Operating loss from discontinued operations (44,681) (11,936) (318) (56,935) Interest expense — — — — Loss from discontinued operations before income taxes (44,681) (11,936) (318) (56,935) Income tax expense (benefit) — — — — Net loss from discontinued operations $ (44,681) $ (11,936) $ (318) $ (56,935) Three Months Ended June 30, 2022 Bright HealthCare - Commercial Bright HealthCare Other Total Revenue: Premium revenue $ 961,650 $ 403,185 $ — $ 1,364,835 Service revenue 34 — 2,079 2,113 Investment income (loss) 5,462 24 — 5,486 Total revenue from discontinued operations 967,146 403,209 2,079 1,372,434 Operating expenses: Medical costs 858,347 356,442 — 1,214,789 Operating costs 278,878 40,181 3,482 322,541 Intangible assets impairment 6,720 — — 6,720 Depreciation and amortization — 4,416 536 4,952 Total operating expenses from discontinued operations 1,143,945 401,039 4,018 1,549,002 Operating loss from discontinued operations (176,799) 2,170 (1,939) (176,568) Interest expense — — — — Loss from discontinued operations before income taxes (176,799) 2,170 (1,939) (176,568) Income tax expense (benefit) — — — — Net loss from discontinued operations $ (176,799) $ 2,170 $ (1,939) $ (176,568) Six Months Ended June 30, 2023 Bright HealthCare - Commercial Bright HealthCare Other Total Revenue: Premium revenue $ (14,588) $ 896,849 $ — $ 882,261 Service revenue 30 — 2,383 2,413 Investment income (loss) 42,011 438 — 42,449 Total revenue from discontinued operations 27,453 897,287 2,383 927,123 Operating expenses: Medical costs 60,602 828,839 — 889,441 Operating costs 91,293 110,628 2,367 204,288 Depreciation and amortization — 5,872 — 5,872 Total operating expenses from discontinued operations 151,895 945,339 2,367 1,099,601 Operating loss from discontinued operations (124,442) (48,052) 16 (172,478) Interest expense — — — — Loss from discontinued operations before income taxes (124,442) (48,052) 16 (172,478) Income tax expense (benefit) — — — — Net loss from discontinued operations $ (124,442) $ (48,052) $ 16 $ (172,478) Six Months Ended June 30, 2022 Bright HealthCare - Commercial Bright HealthCare Other Total Revenue: Premium revenue $ 2,141,963 $ 816,372 $ — $ 2,958,335 Service revenue 70 — 4,242 4,312 Investment income (loss) 6,250 47 — 6,297 Other income — — 799 799 Total revenue from discontinued operations 2,148,283 816,419 5,041 2,969,743 Operating expenses: Medical costs 1,804,267 754,770 — 2,559,037 Operating costs 544,378 83,502 8,532 636,412 Intangible assets impairment 6,720 — — 6,720 Depreciation and amortization 145 8,875 914 9,934 Total operating expenses from discontinued operations 2,355,510 847,147 9,446 3,212,103 Operating loss from discontinued operations (207,227) (30,728) (4,405) (242,360) Interest expense — — — — Loss from discontinued operations before income taxes (207,227) (30,728) (4,405) (242,360) Income tax expense (benefit) (2) (6,741) 2 (6,741) Net loss from discontinued operations $ (207,225) $ (23,987) $ (4,407) $ (235,619) The following table presents cash flows from operating and investing activities for discontinued operations for the six months ended June 30, 2023 (in thousands) : Cash used in operating activities - discontinued operations (667,237) Cash provided by investing activities - discontinued operations 157,048 Assets and liabilities of discontinued operations were as follows (in thousands) : June 30, 2023 Bright HealthCare - Commercial Bright HealthCare Total Assets Current assets: Cash and cash equivalents $ 917,328 $ 335,453 $ 1,252,781 Short-term investments 991,106 4,308 995,414 Accounts receivable, net of allowance 1,915 48,856 50,771 Prepaids and other current assets 57,465 156,817 214,282 Property, equipment and capitalized software, net — 19,948 19,948 Goodwill — 358,693 358,693 Intangible assets, net — 138,981 138,981 Current assets of discontinued operations 1,967,814 1,063,056 3,030,870 Total assets of discontinued operations $ 1,967,814 $ 1,063,056 $ 3,030,870 Liabilities Current liabilities: Medical costs payable $ 98,482 $ 251,269 $ 349,751 Accounts payable 38,802 8,564 47,366 Risk adjustment payable 1,953,502 1,313 1,954,815 Unearned revenue — 142,698 142,698 Other current liabilities 20,738 69,522 90,260 Current liabilities of discontinued operations 2,111,524 473,366 2,584,890 Total liabilities of discontinued operations $ 2,111,524 $ 473,366 $ 2,584,890 December 31, 2022 Bright HealthCare - Commercial Bright HealthCare Other Total Assets Current assets: Cash and cash equivalents $ 1,469,577 $ 244,616 $ 1,091 $ 1,715,284 Short-term investments 1,129,800 3,972 — 1,133,772 Accounts receivable, net of allowance 4,167 59,308 1,636 65,111 Prepaids and other current assets 187,818 85,479 — 273,297 Current assets of discontinued operations 2,791,362 393,375 2,727 3,187,464 Other assets: Property, equipment and capitalized software, net — 21,298 — 21,298 Goodwill — 358,693 — 358,693 Intangible assets, net — 144,131 — 144,131 Other non-current assets — 4,995 — 4,995 Other assets of discontinued operations — 529,117 — 529,117 Total assets of discontinued operations $ 2,791,362 $ 922,492 $ 2,727 $ 3,716,581 Liabilities Current liabilities: Medical costs payable $ 691,221 $ 290,296 $ — $ 981,517 Accounts payable 160,707 10,858 — 171,565 Risk adjustment payable 1,942,643 1,247 — 1,943,890 Unearned revenue — — 242 242 Other current liabilities 19,373 40,002 647 60,022 Current liabilities of discontinued operations 2,813,944 342,403 889 3,157,236 Total liabilities of discontinued operations $ 2,813,944 $ 342,403 $ 889 $ 3,157,236 Revenue Recognition: We record adjustments for changes to the risk adjustment balances for individual policies in premium revenue. The risk adjustment program adjusts premiums based on the demographic factors and health status of each consumer as derived from current-year medical diagnoses as reported throughout the year. Under the risk adjustment program, a risk score is assigned to each covered consumer to determine an average risk score at the individual and small-group level by legal entity in a particular market in a state. Additionally, an average risk score is determined for the entire subject population for each market in each state. Settlements are determined on a net basis by legal entity and state and are made in the middle of the year following the end of the contract year. Each health insurance issuer’s average risk score is compared to the state’s average risk score. Risk adjustment is subject to audit by the U.S. Department of Health and Human Services (“HHS”), which could result in future payments applicable to benefit years. Premium revenue under the MA program includes CMS monthly premiums that are risk adjusted based on CMS defined formulas using consumer demographics and hierarchical condition category codes (“HCC risk scores”) calculated based on historical data submitted to CMS on a lagged basis. Risk Adjustment Factor-related (“RAF”) premiums settle between CMS and the Company during both a midyear and final reconciliation process. Due to the lagged nature of the reconciliation and settlement, RAF-related premiums are estimated based on the lagged information that we submitted to CMS. The accuracy of the data submissions to CMS used in the RAF reconciliation are subject to CMS audit under the RADV audits and could result in future adjustments to premiums. Restructuring Charges: As a result of the strategic changes, we announced and have taken actions to restructure the Company’s workforce and reduce expenses based on our updated business model. There were no restructuring charges for the three and six months ended June 30, 2022 . Restructuring charges within our discontinued operations for the three and six months ended June 30, 2023 were as follows (in thousands) : Three Months Ended June 30, Six Months Ended June 30, 2023 2023 Employee termination benefits $ 213 $ 3,177 Long-lived asset impairments 2,489 7,429 Contract termination and other costs (1,041) (989) Total discontinued operations restructuring charges $ 1,661 $ 9,617 Restructuring accrual activity recorded by major type for the six months ended June 30, 2023 was as follows (in thousands) : Employee Termination Benefits Contract Termination Costs Total Balance at January 1, 2023 $ 16,053 $ 29,053 $ 45,106 Charges 3,177 (989) 2,188 Cash payments (12,409) 199 (12,210) Balance at June 30, 2023 $ 6,821 $ 28,263 $ 35,084 Employee termination benefits are recorded within Other current liabilities of discontinued operations while contract termination costs are recorded within Accounts payable of discontinued operations. Fixed Maturity Securities: Available-for-sale securities within our discontinued operations are reported at fair value as of June 30, 2023 and December 31, 2022. Held-to-maturity securities are reported at amortized cost as of June 30, 2023 and December 31, 2022. The following is a summary of our investment securities (in thousands) : June 30, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Carrying Value Cash equivalents $ 564,557 $ 14 $ — $ 564,571 Available for sale: U.S. government and agency obligations 975,759 128 (270) 975,617 Corporate obligations 3,025 — (27) 2,998 State and municipal obligations 4,169 — (8) 4,161 Certificates of deposit 3,661 — — 3,661 Mortgage backed securities 1,695 — (149) 1,546 Asset-backed securities 698 3 — 701 Total available-for-sale securities 989,007 131 (454) 988,684 Held to maturity: U.S. government and agency obligations 6,512 — (113) 6,399 Certificates of deposit 331 — — 331 Total held-to-maturity securities 6,843 — (113) 6,730 Total investments $ 1,560,407 $ 145 $ (567) $ 1,559,985 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Carrying Value Cash equivalents $ 963,062 $ 32 $ — $ 963,094 Available for sale: U.S. government and agency obligations 372,244 1 (3,239) 369,006 Corporate obligations 520,619 521 (714) 520,426 State and municipal obligations 10,308 — (96) 10,212 Certificates of deposit 12,012 — (2) 12,010 Mortgage-backed securities 154,167 46 (156) 154,057 Asset backed securities 59,289 — — 59,289 Other 386 — (14) 372 Total available-for-sale securities 1,129,025 568 (4,221) 1,125,372 Held to maturity: U.S. government and agency obligations 6,622 — (158) 6,464 Certificates of deposit 1,936 — — 1,936 Total held-to-maturity securities 8,558 — (158) 8,400 Total investments $ 2,100,645 $ 600 $ (4,379) $ 2,096,866 We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. At each reporting period, we evaluate securities for impairment when the fair value of the investment is less than its amortized cost. We evaluated the underlying credit quality and credit ratings of the issuers, noting no significant deterioration since purchase. Fair Value Measurements: As of June 30, 2023, investments and cash equivalents within our discontinued operations were comprised of $1.5 billion and $53.2 million with fair value measurements of Level 1 and Level 2, respectively. As of December 31, 2022, the investments and cash equivalents within our discontinued operations were comprised of $1.3 billion and $826.0 million with fair value measurements of Level 1 and Level 2, respectively. Medical Costs Payable: The table below details the components making up the medical costs payable within current liabilities of discontinued operations (in thousands) : Bright HealthCare - Commercial Bright HealthCare June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 Claims unpaid $ 49,474 $ 60,856 $ 41,236 $ 41,188 Provider incentive payable 1,454 310 31,424 40,908 Claims adjustment expense liability 6,993 46,490 4,981 6,732 Incurred but not reported (IBNR) 40,562 583,564 173,628 201,468 Total medical costs payable of discontinued operations $ 98,483 $ 691,220 $ 251,269 $ 290,296 The following table shows the components of the change in medical costs payable for the six months ended June 30 (in thousand s) : Bright Health Care 2023 2022 Medical costs payable - January 1 $ 290,296 $ 240,854 Incurred related to: Current year 810,631 747,953 Prior year 16,058 8,662 Total incurred 826,689 756,615 Paid related to: Current year 602,338 523,662 Prior year 263,378 206,329 Total paid 865,716 729,991 Medical costs payable - June 30 $ 251,269 $ 267,478 Risk Adjustment: We record adjustments for changes to the risk adjustment balances for individual policies in premium revenue. The risk adjustment program adjusts premiums based on the demographic factors and health status of each consumer as derived from current-year medical diagnoses as reported throughout the year. Under the risk adjustment program, a risk score is assigned to each covered consumer to determine an average risk score at the individual and small-group level by legal entity in a particular market in a state. Additionally, an average risk score is determined for the entire subject population for each market in each state. Settlements are determined on a net basis by legal entity and state and are made in the middle of the year following the end of the contract year. Each health insurance issuer’s average risk score is compared to the state’s average risk score. Risk adjustment is subject to audit by HHS, which could result in future payments applicable to benefit years.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On August 4, 2023, we entered into the New Credit Agreement to provide for a credit facility pursuant to which, among other things, the lenders have provided $60.0 million delayed draw term loan commitments. We may borrow delayed draw term loans under such commitments at any time and from time to time on or prior to the date that is nine months after the effective date of the New Credit Agreement, subject to the satisfaction or waiver of customary conditions. Borrowings under the New Credit Agreement accrue interest at a rate per annum of 15.00%, payable quarterly in arrears at our election, subject to limitations set forth in the Fourth Waiver in respect of cash payments under the New Credit Agreement, either in cash or “in kind” by adding the amount of accrued interest to the principal amount of the outstanding loans under the New Credit Agreement. Also on August 4, 2023, we entered into the Fourth Waiver under the Credit Agreement. The Fourth Waiver amends and restates the Third Waiver by, among other things, permanently waiving compliance with the minimum liquidity covenant set forth in Section 11.12.2 of the Credit Agreement, which waiver under the Third Waiver previously was temporary and would have expired on August 29, 2023. From August 4, 2023 until the Credit Agreement is terminated and all outstanding loans thereunder are repaid, we will be subject to a minimum liquidity covenant of not less than $25.0 million. In addition, on August 4, 2023, we entered into the Warrantholders Agreement setting forth the rights and obligations of us and the Holders of the Warrants and providing for the issuance of the Warrants to purchase up to 1,656,789 shares of our common stock. See Note 1, Organization and Basis of Presentation , for additional information regarding the New Credit Agreement, the Fourth Waiver and the Warrantholders Agreement.

ORGANIZATION AND BASIS OF PRE_2

ORGANIZATION AND BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation: The condensed consolidated financial statements include the accounts of Bright Health Group, Inc. and all subsidiaries and controlled companies. All intercompany balances and transactions are eliminated upon consolidation. The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our audited consolidated financial statements, unless the information contained in those disclosures materially changed or is required by GAAP. As such, the condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2022 included in our Form 10-K for the year ended December 31, 2022 (“2022 Form 10-K”). The accompanying condensed consolidated financial statements include all normal recurring adjustments necessary for fair presentation of the interim financial statements.
Reportable Segments	Reportable Segments: During the three months ended June 30, 2023, our reportable segments changed. We now report our operating results through four reportable segments: Care Delivery and Care Solutions within continuing operations and Bright HealthCare - Commercial and Bright HealthCare within discontinued operations. The Care Delivery and Care Solutions segments were formerly within the Consumer Care segment. The updates to our reportable segments conform with the Company’s chief operating decision maker’s (“CODM”) view of our ongoing operations. See Note 10, Segments and Geographic Information
Discontinued Operations	Discontinued Operations: H
Use of Estimates	Use of Estimates: The preparation of our condensed consolidated financial statements in conformance with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Our most significant estimates include medical costs payable, ACO REACH performance year receivable and obligation, shared savings and shared losses for our capitation contracts, and valuation and impairment of goodwill and other intangible assets. Actual results could differ from these estimate
Going Concern	Going Concern: The condensed consolidated financial statements have been prepared in accordance with GAAP applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has a history of operating losses, and we generated a net loss of $258.1 million for the six months ended June 30, 2023. Additionally, the Company experienced negative operating cash flows primarily related to our discontinued Bright HealthCare – Commercial segment for the six months ended June 30, 2023, requiring additional cash to be infused to satisfy statutory capital requirements. The Company’s IFP discontinued operations will continue to experience negative cash flows through the third quarter of 2023, as it pays out the 2022 IFP risk adjustment obligations. Although the Company has sufficient cash to satisfy its IFP risk adjustment obligations in full in certain states, the Company is working with its regulators regarding the status of its obligations in certain other states. In addition, the Company’s $350.0 million revolving credit agreement with a syndicate of banks (the “Credit Agreement”), matures on February 28, 2024. On March 1, 2023, the Company disclosed that during the First Quarter of 2023, it had breached the minimum liquidity covenant contained in the Credit Agreement. On June 29, 2023, the Company entered into a second amended and restated limited waiver and consent (the “Third Waiver”) under the Credit Agreement. The Third Waiver amended and restated the amended and restated limited waiver and consent entered into by the Company under the Credit Agreement on April 28, 2023 (the “Second Waiver”), which had amended and restated the limited waiver and consent entered into by the Company under the Credit Agreement on February 28, 2023 (the “Original Waiver”). The Third Waiver amended the Second Waiver and the Original Waiver by, among other things, extending the temporary waiver of compliance with the minimum liquidity covenant set forth in Section 11.12.2 of the Credit Agreement, which spanned from January 25, 2023 to June 30, 2023 under the Original Waiver and the Second Waiver, to January 25, 2023 to August 29, 2023 (the “Extended Waiver Period”). The Third Waiver also, among other things, added covenants (a) requiring the Company to deliver by July 17, 2023, an agreed term sheet for an equity or debt financing (the “Bridge Financing”) to support the Company’s ongoing operating cash needs through December 31, 2023 and, by July 31, 2023 (extended to August 4, 2023), definitive documentation for the Bridge Financing and an updated budget of the Company, (b) prohibiting the incurrence of certain types of debt and (c) requiring the Company not to request any interest period for any term SOFR borrowing other than a one-month interest period. On August 4, 2023, the Company entered into a Credit Agreement (as amended, supplemented, restated or otherwise modified from time to time, the “New Credit Agreement”), among the Company, NEA 18 Venture Growth Equity, L.P. (“NEA”) and the lenders from time to time party thereto (together with NEA and each of their respective successors and assigns, the “Lenders”), to provide for a credit facility pursuant to which, among other things, the lenders have provided $60.0 million delayed draw term loan commitments. The Company may borrow delayed draw term loans under such commitments at any time and from time to time on or prior to the date that is nine months after the effective date of the New Credit Agreement, subject to the satisfaction or waiver of customary conditions. Borrowings under the New Credit Agreement accrue interest at a rate per annum of 15.00%, payable quarterly in arrears at the Company’s election, subject to limitations set forth in the Fourth Waiver (defined below) in respect of cash payments under the New Credit Agreement, either in cash or “in kind” by adding the amount of accrued interest to the principal amount of the outstanding loans under the New Credit Agreement. The New Credit Agreement contains covenants that, among other things, restrict the ability of the Company and its subsidiaries to make certain restricted payments, incur additional debt, engage in certain asset sales, mergers, acquisitions or similar transactions, create liens on assets, engage in certain transactions with affiliates, change its business or make investments. The New Credit Agreement constitutes the Bridge Financing referred to in the Third Waiver. On August 4, 2023, the Company entered into a third amended and restated limited waiver and consent (the “Fourth Waiver”) under the Credit Agreement. The Fourth Waiver amends and restates the Third Waiver by, among other things, permanently waiving compliance with the minimum liquidity covenant set forth in Section 11.12.2 of the Credit Agreement, which waiver under the Third Waiver previously was temporary and would have expired on August 29, 2023. From August 4, 2023 until the Credit Agreement is terminated and all outstanding loans thereunder are repaid, the Company will be subject to a minimum liquidity covenant of not less than $25.0 million. The Fourth Waiver also, among other things, (a) removes from the credit agreement in its entirety the covenant requiring maintenance of a maximum total debt to capitalization ratio, which absent such removal would have applied after September 30, 2023, (b) prohibits the incurrence of certain types of debt and (c) requires the Company not to request any interest period for any Term Benchmark borrowing other than a one-month interest period. In connection with the New Credit Agreement, on August 4, 2023, the Company and the Lenders entered into a warrantholders agreement (the “Warrantholders Agreement”) setting forth the rights and obligations of the Company and the Lenders as holders (in such capacity, the “Holders”) of the warrants to acquire shares of Common Stock at an exercise price of $0.01 per share (the “Warrants”), and providing for the issuance of the Warrants to purchase up to 1,656,789 shares of the Company’s common stock. Any future non-compliance with the covenants under the Credit Agreement or the Fourth Waiver, or termination of our agreement to sell our Medicare Advantage business in California to Molina Healthcare, Inc. (“the Molina Purchase Agreement”), may result in the obligations under the Credit Agreement being accelerated. Based on our projected cash flows and absent any other action, the Company may not meet certain covenants under the Credit Agreement, the Fourth Waiver or the New Credit Agreement which may result in the obligations under the Credit Agreement and New Credit Agreement being accelerated. The Company will require additional liquidity to meet its obligations as they come due in the 12 months following the date the condensed consolidated financial statements contained in this Quarterly Report are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In response to these conditions, management has implemented a restructuring plan to reduce capital needs and our operating expenses in the future to drive positive operating cash flow and increase liquidity. The Company’s Bright HealthCare - Commercial business exited the ACA marketplace at the end of the 2022 plan year. In addition to our market exits, management is in the process of executing upon additional restructuring activities, which include reducing our workforce, exiting excess office space, and terminating or restructuring contracts. The Company closed on a $175.0 million capital raise in October 2022 to fund our continuing operations as further described in Note 7, Redeemable Convertible Preferred Stock . On June 30, 2023, the Company entered into the Molina Purchase Agreement to sell its California Medicare Advantage business, which consists of Brand New Day and Central Health Plan, for total purchase consideration of $600.0 million, subject to regulatory approval and other closing conditions. The closing of this transaction is expected to occur by early 2024. Further, as described above, the Company entered into the New Credit Agreement on August 4, 2023. In the event the Company is unable to execute the sale of the California Medicare Advantage business, obtain additional financing or take other management actions, among other potential consequences, we forecast we will be unable to satisfy our obligations. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements: There are no accounting pronouncements that were recently issued and not yet adopted or adopted since our audited consolidated financial statements were issued that had, or are expected to have, a material impact on our consolidated financial position, results of operations, or cash flows.

ORGANIZATION AND BASIS OF PRE_3

ORGANIZATION AND BASIS OF PRESENTATION (Tables)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Operating Costs by Functional Classification	Operating Costs: Our operating costs, by functional classification for the three and six months ended June 30, 2023 and 2022, are as follows (in thousand s) : Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Compensation and fringe benefits $ 42,413 $ 55,497 $ 101,037 $ 125,008 Professional fees 13,771 6,962 19,619 15,745 Marketing and selling expenses 630 842 1,204 2,270 General and administrative expenses 7,766 5,999 15,223 13,917 Other operating expenses 5,700 9,697 12,715 18,845 Total operating costs $ 70,280 $ 78,997 $ 149,798 $ 175,785

RESTRUCTURING CHARGES (Tables)

RESTRUCTURING CHARGES (Tables)	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	Restructuring charges by reportable segment and corporate for the periods ended June 30 were as follows (in thousands) : Three Months Ended June 30, 2023 Care Delivery Care Solutions Corporate & Eliminations Total Employee termination benefits $ — $ — $ 1,387 $ 1,387 Long-lived asset impairments — — — — Contract termination and other costs — — (102) (102) Total continuing operations $ — $ — $ 1,285 $ 1,285 Three Months Ended June 30, 2022 Care Delivery Care Solutions Corporate & Eliminations Total Employee termination benefits $ — $ — $ 2,604 $ 2,604 Long-lived asset impairments — — — — Contract termination and other costs — — 189 189 Total continuing operations $ — $ — $ 2,793 $ 2,793 Six Months Ended June 30, 2023 Care Delivery Care Solutions Corporate & Eliminations Total Employee termination benefits $ (44) $ 3 $ 662 $ 621 Long-lived asset impairments — — 880 880 Contract termination and other costs — — 85 85 Total continuing operations $ (44) $ 3 $ 1,627 $ 1,586 Six Months Ended June 30, 2022 Care Delivery Care Solutions Corporate & Eliminations Total Employee termination benefits $ — $ — $ 8,701 $ 8,701 Long-lived asset impairments — — — — Contract termination and other costs — — 956 956 Total continuing operations $ — $ — $ 9,657 $ 9,657 June 30, 2023 were as follows (in thousands) : Three Months Ended June 30, Six Months Ended June 30, 2023 2023 Employee termination benefits $ 213 $ 3,177 Long-lived asset impairments 2,489 7,429 Contract termination and other costs (1,041) (989) Total discontinued operations restructuring charges $ 1,661 $ 9,617
Schedule of Restructuring Reserve by Type of Cost	Restructuring accrual activity recorded by major type for the six months ended June 30, 2023 were as follows (in thousands) : Employee Termination Benefits Contract Termination Costs Total Balance at January 1, 2023 $ 24,077 $ — $ 24,077 Charges 621 85 706 Cash payments (16,935) (85) (17,020) Balance at June 30, 2023 $ 7,763 $ — $ 7,763 Restructuring accrual activity recorded by major type for the six months ended June 30, 2023 was as follows (in thousands) : Employee Termination Benefits Contract Termination Costs Total Balance at January 1, 2023 $ 16,053 $ 29,053 $ 45,106 Charges 3,177 (989) 2,188 Cash payments (12,409) 199 (12,210) Balance at June 30, 2023 $ 6,821 $ 28,263 $ 35,084

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes in the carrying value of goodwill by reportable segment were as follows (in thousands) : June 30, 2023 December 31, 2022 Gross Carrying Cumulative Gross Carrying Cumulative Care Delivery $ 401,385 $ — $ 401,385 $ — Total $ 401,385 $ — $ 401,385 $ —
Schedule of Finite-Lived Intangible Assets	The gross carrying value and accumulated amortization for definite-lived intangible assets were as follows (in thousand s) : June 30, 2023 December 31, 2022 Gross Carrying Accumulated Amortization Gross Carrying Accumulated Amortization Customer relationships $ 80,021 $ 21,910 $ 80,021 $ 17,655 Trade names 48,361 7,388 48,361 5,776 Total $ 128,382 $ 29,298 $ 128,382 $ 23,431
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated amortization expense relating to intangible assets for the remainder of 2023 and for each of the next five full years ending December 31 is as follows (in thousand s) : 2023 (July-December) $ 5,846 2024 $ 11,574 2025 $ 11,574 2026 $ 11,574 2027 $ 11,574 2028 $ 10,295

MEDICAL COSTS PAYABLE (Tables)

MEDICAL COSTS PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2023
Insurance [Abstract]
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense	The following table shows the components of the change in medical costs payable for the six months ended June 30 (in thousand s) : June 30, 2023 2022 Medical costs payable - January 1 $ 116,021 $ 6,764 Incurred related to: Current year 504,307 312,339 Prior year 1,029 (2,089) Total incurred 505,336 310,250 Paid related to: Current year 347,629 210,452 Prior year 93,873 4,547 Total paid 441,502 214,999 Medical costs payable - June 30 $ 179,855 $ 102,015 The table below details the components making up the medical costs payable as of June 30 (in thousand s) : June 30, 2023 2022 Provider incentive payable $ 27,884 $ — Incurred but not reported (IBNR) 151,971 102,015 Total medical costs payable $ 179,855 $ 102,015 table below details the components making up the medical costs payable within current liabilities of discontinued operations (in thousands) : Bright HealthCare - Commercial Bright HealthCare June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 Claims unpaid $ 49,474 $ 60,856 $ 41,236 $ 41,188 Provider incentive payable 1,454 310 31,424 40,908 Claims adjustment expense liability 6,993 46,490 4,981 6,732 Incurred but not reported (IBNR) 40,562 583,564 173,628 201,468 Total medical costs payable of discontinued operations $ 98,483 $ 691,220 $ 251,269 $ 290,296 The following table shows the components of the change in medical costs payable for the six months ended June 30 (in thousand s) : Bright Health Care 2023 2022 Medical costs payable - January 1 $ 290,296 $ 240,854 Incurred related to: Current year 810,631 747,953 Prior year 16,058 8,662 Total incurred 826,689 756,615 Paid related to: Current year 602,338 523,662 Prior year 263,378 206,329 Total paid 865,716 729,991 Medical costs payable - June 30 $ 251,269 $ 267,478

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Payment Arrangement, Option, Activity	The activity for stock options for the six months ended June 30, 2023 is as follows (in thousand s, except exercise price and contractual life) : Shares Weighted-Average Weighted-Average Aggregate Outstanding at January 1, 2023 804 $ 145.60 6.7 $ 6,560 Granted — — Exercised — — Forfeited (26) 220.21 Expired (58) 151.36 Outstanding at June 30, 2023 720 $ 142.13 5.2 $ 569
Share-based Payment Arrangement, Restricted Stock Unit, Activity	The following table summarizes RSU award activity for the six months ended June 30, 2023 (in thousand s, except weighted average grant date fair value) : Number of RSUs Weighted Average Grant Date Fair Value Unvested RSUs at December 31, 2022 470 $ 189.88 Granted 964 32.24 Vested (94) 129.70 Forfeited (232) 101.45 Unvested RSUs at June 30, 2023 1,108 $ 72.57
Share-based Payment Arrangement, Performance Shares, Activity	The following table summarizes PSU award activity for the six months ended June 30, 2023 (in thousand s, except weighted average grant date fair value) : Number of PSUs Weighted Average Grant Date Fair Value Unvested PSUs at December 31, 2022 131 $ 744.00 Granted — — Forfeited — — Unvested PSUs at June 30, 2023 131 $ 744.00

NET LOSS PER SHARE (Tables)

NET LOSS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the three and six months ended June 30 (in thousand s, except for per share amounts) : Three Months Ended Six Months Ended 2023 2022 2023 2022 Loss from continuing operations, net noncontrolling interests and accrued preferred stock dividends $ (68,070) $ (107,559) $ (139,432) $ (252,680) Loss from discontinued operations (56,935) (176,568) (172,478) (235,619) Net loss attributable to Bright Health Group, Inc. common shareholders $ (125,005) $ (284,127) $ (311,910) $ (488,299) Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted 7,962 7,865 7,928 7,862 Basic and diluted loss per share attributable to Bright Health Group, Inc. common shareholders Continuing operations $ (8.55) $ (13.68) $ (17.59) $ (32.14) Discontinued operations $ (7.15) $ (22.45) $ (21.76) $ (29.97) Net loss per share attributable to common stockholders, basic and diluted $ (15.70) $ (36.13) $ (39.35) $ (62.11)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive effect for the six months ended June 30 (in thousand s) : Six Months Ended 2023 2022 Redeemable convertible preferred stock (as converted to common stock) 4,081 2,112 Stock options to purchase common stock 720 853 Restricted stock units 1,108 458 Total 5,909 3,423

SEGMENTS AND GEOGRAPHIC INFOR_2

SEGMENTS AND GEOGRAPHIC INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of Reportable Segment Financial Information	The following tables present the reportable segment financial information for the three and six months ended June 30, 2023 and 2022 (in thousand s) : Three Months Ended June 30, 2023 Care Delivery Care Solutions Corporate & Eliminations Consolidated Capitated revenue $ 49,764 $ — $ — $ 49,764 ACO REACH revenue — 236,994 — 236,994 Service revenue 10,530 692 — 11,222 Investment income (loss) — — 2 2 Total unaffiliated revenue 60,294 237,686 2 297,982 Affiliated revenue 5,774 — (5,774) — Total segment revenue 66,068 237,686 (5,772) 297,982 Operating income (loss) 11,031 2,996 (37,441) (23,414) Depreciation and amortization 3,178 — 1,493 4,671 Restructuring charges — — 1,285 1,285 Three Months Ended June 30, 2022 Care Delivery Care Solutions Corporate & Eliminations Consolidated Capitated revenue $ 17,641 $ — $ — $ 17,641 ACO REACH revenue — 137,205 — 137,205 Service revenue 10,691 41 — 10,732 Investment income (loss) — — (16,238) (16,238) Total unaffiliated revenue 28,332 137,246 (16,238) 149,340 Affiliated revenue 204,271 — (204,271) — Total segment revenue 232,603 137,246 (220,509) 149,340 Operating income (loss) (698) 825 (71,646) (71,519) Depreciation and amortization 6,369 — 1,907 8,276 Restructuring charges — — 2,793 2,793 Six Months Ended June 30, 2023 Care Delivery Care Solutions Corporate & Eliminations Consolidated Capitated revenue $ 99,312 $ — $ — $ 99,312 ACO REACH revenue — 476,801 — 476,801 Service revenue 21,466 943 — 22,409 Investment income (loss) — — 10 10 Total unaffiliated revenue 120,778 477,744 10 598,532 Affiliated revenue 7,969 — (7,969) — Total segment revenue 128,747 477,744 (7,959) 598,532 Operating income (loss) 17,667 1,487 (87,440) (68,286) Depreciation and amortization 6,310 — 3,844 10,154 Restructuring charges — — 1,586 1,586 Six Months Ended June 30, 2022 Care Delivery Care Solutions Corporate & Eliminations Consolidated Capitated revenue $ 46,289 $ — $ — $ 46,289 ACO REACH revenue — 320,002 — 320,002 Service revenue 20,910 52 — 20,962 Investment income (loss) — — (57,149) (57,149) Total unaffiliated revenue 67,199 320,054 (57,149) 330,104 Affiliated revenue 572,391 — (572,391) — Total segment revenue 639,590 320,054 (629,540) 330,104 Operating income (loss) (22,749) 4,989 (164,163) (181,923) Depreciation and amortization 12,745 — 3,591 16,336 Restructuring charges — — 9,657 9,657

REDEEMABLE NONCONTROLLING INT_2

REDEEMABLE NONCONTROLLING INTEREST (Tables)	6 Months Ended
	Jun. 30, 2023
Noncontrolling Interest [Abstract]
Schedule of Redeemable Noncontrolling Interest	The following table provides details of our redeemable noncontrolling interest activity for the three and six months e nded June 30, 2023 and 2022 (in thousand s) : 2023 2022 Balance at January 1 $ 219,758 $ 128,407 Earnings attributable to noncontrolling interest 1,421 (2,681) Distribution to noncontrolling interest holders (1,805) — Measurement adjustment 4,129 17,285 Balance at March 31 $ 223,503 $ 143,011 Earnings attributable to noncontrolling interest 3,139 3,625 Distribution to noncontrolling interest holders (3,147) (1,894) Measurement adjustment 21,066 19,712 Balance at June 30 $ 244,561 $ 164,454

ACO REACH (Tables)

ACO REACH (Tables)	6 Months Ended
	Jun. 30, 2023
Direct Contracting [Abstract]
Schedule Of Performance Guarantees	The tables below include the financial statement impacts of the performance guarantee at June 30, 2023 and for the three and six-month period then ended ( in thousands ): June 30, 2023 December 31, 2022 ACO REACH performance year receivable (1) $ 623,609 $ 99,181 ACO REACH performance year obligation 474,700 — (1) We estimate there to be $144.3 million and $1.2 million in-network and out-of-network claims incurred by beneficiaries aligned to our REACH ACOs but not reported as of June 30, 2023 and December 31, 2022, respectively; this is included in medical costs payable on the Condensed Consolidated Balance Sheets. Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Amortization of ACO REACH performance year receivable (1) $ 249,449 $ 156,808 $ 424,972 $ 231,935 Amortization of ACO REACH performance year obligation 234,893 164,404 474,700 347,201 ACO REACH revenue 236,994 137,205 476,801 320,002 (1) The amortization of the ACO REACH performance year receivable includes $99.2 million related to the amortization of the prior year receivable.

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	6 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations	The financial results of discontinued operations by major line item for the periods ended June 30 were as follows (in thousands) : Three Months Ended June 30, 2023 Bright HealthCare - Commercial Bright HealthCare Other Total Revenue: Premium revenue $ (15,354) $ 443,532 $ — $ 428,178 Service revenue — — — — Investment income (loss) 21,120 400 — 21,520 Total revenue from discontinued operations 5,766 443,932 — 449,698 Operating expenses: Medical costs 14,588 400,114 — 414,702 Operating costs 35,859 54,289 318 90,466 Depreciation and amortization — 1,465 — 1,465 Total operating expenses from discontinued operations 50,447 455,868 318 506,633 Operating loss from discontinued operations (44,681) (11,936) (318) (56,935) Interest expense — — — — Loss from discontinued operations before income taxes (44,681) (11,936) (318) (56,935) Income tax expense (benefit) — — — — Net loss from discontinued operations $ (44,681) $ (11,936) $ (318) $ (56,935) Three Months Ended June 30, 2022 Bright HealthCare - Commercial Bright HealthCare Other Total Revenue: Premium revenue $ 961,650 $ 403,185 $ — $ 1,364,835 Service revenue 34 — 2,079 2,113 Investment income (loss) 5,462 24 — 5,486 Total revenue from discontinued operations 967,146 403,209 2,079 1,372,434 Operating expenses: Medical costs 858,347 356,442 — 1,214,789 Operating costs 278,878 40,181 3,482 322,541 Intangible assets impairment 6,720 — — 6,720 Depreciation and amortization — 4,416 536 4,952 Total operating expenses from discontinued operations 1,143,945 401,039 4,018 1,549,002 Operating loss from discontinued operations (176,799) 2,170 (1,939) (176,568) Interest expense — — — — Loss from discontinued operations before income taxes (176,799) 2,170 (1,939) (176,568) Income tax expense (benefit) — — — — Net loss from discontinued operations $ (176,799) $ 2,170 $ (1,939) $ (176,568) Six Months Ended June 30, 2023 Bright HealthCare - Commercial Bright HealthCare Other Total Revenue: Premium revenue $ (14,588) $ 896,849 $ — $ 882,261 Service revenue 30 — 2,383 2,413 Investment income (loss) 42,011 438 — 42,449 Total revenue from discontinued operations 27,453 897,287 2,383 927,123 Operating expenses: Medical costs 60,602 828,839 — 889,441 Operating costs 91,293 110,628 2,367 204,288 Depreciation and amortization — 5,872 — 5,872 Total operating expenses from discontinued operations 151,895 945,339 2,367 1,099,601 Operating loss from discontinued operations (124,442) (48,052) 16 (172,478) Interest expense — — — — Loss from discontinued operations before income taxes (124,442) (48,052) 16 (172,478) Income tax expense (benefit) — — — — Net loss from discontinued operations $ (124,442) $ (48,052) $ 16 $ (172,478) Six Months Ended June 30, 2022 Bright HealthCare - Commercial Bright HealthCare Other Total Revenue: Premium revenue $ 2,141,963 $ 816,372 $ — $ 2,958,335 Service revenue 70 — 4,242 4,312 Investment income (loss) 6,250 47 — 6,297 Other income — — 799 799 Total revenue from discontinued operations 2,148,283 816,419 5,041 2,969,743 Operating expenses: Medical costs 1,804,267 754,770 — 2,559,037 Operating costs 544,378 83,502 8,532 636,412 Intangible assets impairment 6,720 — — 6,720 Depreciation and amortization 145 8,875 914 9,934 Total operating expenses from discontinued operations 2,355,510 847,147 9,446 3,212,103 Operating loss from discontinued operations (207,227) (30,728) (4,405) (242,360) Interest expense — — — — Loss from discontinued operations before income taxes (207,227) (30,728) (4,405) (242,360) Income tax expense (benefit) (2) (6,741) 2 (6,741) Net loss from discontinued operations $ (207,225) $ (23,987) $ (4,407) $ (235,619) The following table presents cash flows from operating and investing activities for discontinued operations for the six months ended June 30, 2023 (in thousands) : Cash used in operating activities - discontinued operations (667,237) Cash provided by investing activities - discontinued operations 157,048 Assets and liabilities of discontinued operations were as follows (in thousands) : June 30, 2023 Bright HealthCare - Commercial Bright HealthCare Total Assets Current assets: Cash and cash equivalents $ 917,328 $ 335,453 $ 1,252,781 Short-term investments 991,106 4,308 995,414 Accounts receivable, net of allowance 1,915 48,856 50,771 Prepaids and other current assets 57,465 156,817 214,282 Property, equipment and capitalized software, net — 19,948 19,948 Goodwill — 358,693 358,693 Intangible assets, net — 138,981 138,981 Current assets of discontinued operations 1,967,814 1,063,056 3,030,870 Total assets of discontinued operations $ 1,967,814 $ 1,063,056 $ 3,030,870 Liabilities Current liabilities: Medical costs payable $ 98,482 $ 251,269 $ 349,751 Accounts payable 38,802 8,564 47,366 Risk adjustment payable 1,953,502 1,313 1,954,815 Unearned revenue — 142,698 142,698 Other current liabilities 20,738 69,522 90,260 Current liabilities of discontinued operations 2,111,524 473,366 2,584,890 Total liabilities of discontinued operations $ 2,111,524 $ 473,366 $ 2,584,890 December 31, 2022 Bright HealthCare - Commercial Bright HealthCare Other Total Assets Current assets: Cash and cash equivalents $ 1,469,577 $ 244,616 $ 1,091 $ 1,715,284 Short-term investments 1,129,800 3,972 — 1,133,772 Accounts receivable, net of allowance 4,167 59,308 1,636 65,111 Prepaids and other current assets 187,818 85,479 — 273,297 Current assets of discontinued operations 2,791,362 393,375 2,727 3,187,464 Other assets: Property, equipment and capitalized software, net — 21,298 — 21,298 Goodwill — 358,693 — 358,693 Intangible assets, net — 144,131 — 144,131 Other non-current assets — 4,995 — 4,995 Other assets of discontinued operations — 529,117 — 529,117 Total assets of discontinued operations $ 2,791,362 $ 922,492 $ 2,727 $ 3,716,581 Liabilities Current liabilities: Medical costs payable $ 691,221 $ 290,296 $ — $ 981,517 Accounts payable 160,707 10,858 — 171,565 Risk adjustment payable 1,942,643 1,247 — 1,943,890 Unearned revenue — — 242 242 Other current liabilities 19,373 40,002 647 60,022 Current liabilities of discontinued operations 2,813,944 342,403 889 3,157,236 Total liabilities of discontinued operations $ 2,813,944 $ 342,403 $ 889 $ 3,157,236
Schedule of Restructuring and Related Costs	Restructuring charges by reportable segment and corporate for the periods ended June 30 were as follows (in thousands) : Three Months Ended June 30, 2023 Care Delivery Care Solutions Corporate & Eliminations Total Employee termination benefits $ — $ — $ 1,387 $ 1,387 Long-lived asset impairments — — — — Contract termination and other costs — — (102) (102) Total continuing operations $ — $ — $ 1,285 $ 1,285 Three Months Ended June 30, 2022 Care Delivery Care Solutions Corporate & Eliminations Total Employee termination benefits $ — $ — $ 2,604 $ 2,604 Long-lived asset impairments — — — — Contract termination and other costs — — 189 189 Total continuing operations $ — $ — $ 2,793 $ 2,793 Six Months Ended June 30, 2023 Care Delivery Care Solutions Corporate & Eliminations Total Employee termination benefits $ (44) $ 3 $ 662 $ 621 Long-lived asset impairments — — 880 880 Contract termination and other costs — — 85 85 Total continuing operations $ (44) $ 3 $ 1,627 $ 1,586 Six Months Ended June 30, 2022 Care Delivery Care Solutions Corporate & Eliminations Total Employee termination benefits $ — $ — $ 8,701 $ 8,701 Long-lived asset impairments — — — — Contract termination and other costs — — 956 956 Total continuing operations $ — $ — $ 9,657 $ 9,657 June 30, 2023 were as follows (in thousands) : Three Months Ended June 30, Six Months Ended June 30, 2023 2023 Employee termination benefits $ 213 $ 3,177 Long-lived asset impairments 2,489 7,429 Contract termination and other costs (1,041) (989) Total discontinued operations restructuring charges $ 1,661 $ 9,617
Schedule of Restructuring Reserve by Type of Cost	Restructuring accrual activity recorded by major type for the six months ended June 30, 2023 were as follows (in thousands) : Employee Termination Benefits Contract Termination Costs Total Balance at January 1, 2023 $ 24,077 $ — $ 24,077 Charges 621 85 706 Cash payments (16,935) (85) (17,020) Balance at June 30, 2023 $ 7,763 $ — $ 7,763 Restructuring accrual activity recorded by major type for the six months ended June 30, 2023 was as follows (in thousands) : Employee Termination Benefits Contract Termination Costs Total Balance at January 1, 2023 $ 16,053 $ 29,053 $ 45,106 Charges 3,177 (989) 2,188 Cash payments (12,409) 199 (12,210) Balance at June 30, 2023 $ 6,821 $ 28,263 $ 35,084
Schedule of Debt Securities, Available-for-sale	The following is a summary of our investment securities (in thousands) : June 30, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Carrying Value Cash equivalents $ 564,557 $ 14 $ — $ 564,571 Available for sale: U.S. government and agency obligations 975,759 128 (270) 975,617 Corporate obligations 3,025 — (27) 2,998 State and municipal obligations 4,169 — (8) 4,161 Certificates of deposit 3,661 — — 3,661 Mortgage backed securities 1,695 — (149) 1,546 Asset-backed securities 698 3 — 701 Total available-for-sale securities 989,007 131 (454) 988,684 Held to maturity: U.S. government and agency obligations 6,512 — (113) 6,399 Certificates of deposit 331 — — 331 Total held-to-maturity securities 6,843 — (113) 6,730 Total investments $ 1,560,407 $ 145 $ (567) $ 1,559,985 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Carrying Value Cash equivalents $ 963,062 $ 32 $ — $ 963,094 Available for sale: U.S. government and agency obligations 372,244 1 (3,239) 369,006 Corporate obligations 520,619 521 (714) 520,426 State and municipal obligations 10,308 — (96) 10,212 Certificates of deposit 12,012 — (2) 12,010 Mortgage-backed securities 154,167 46 (156) 154,057 Asset backed securities 59,289 — — 59,289 Other 386 — (14) 372 Total available-for-sale securities 1,129,025 568 (4,221) 1,125,372 Held to maturity: U.S. government and agency obligations 6,622 — (158) 6,464 Certificates of deposit 1,936 — — 1,936 Total held-to-maturity securities 8,558 — (158) 8,400 Total investments $ 2,100,645 $ 600 $ (4,379) $ 2,096,866
Schedule of Debt Securities, Held-to-maturity	The following is a summary of our investment securities (in thousands) : June 30, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Carrying Value Cash equivalents $ 564,557 $ 14 $ — $ 564,571 Available for sale: U.S. government and agency obligations 975,759 128 (270) 975,617 Corporate obligations 3,025 — (27) 2,998 State and municipal obligations 4,169 — (8) 4,161 Certificates of deposit 3,661 — — 3,661 Mortgage backed securities 1,695 — (149) 1,546 Asset-backed securities 698 3 — 701 Total available-for-sale securities 989,007 131 (454) 988,684 Held to maturity: U.S. government and agency obligations 6,512 — (113) 6,399 Certificates of deposit 331 — — 331 Total held-to-maturity securities 6,843 — (113) 6,730 Total investments $ 1,560,407 $ 145 $ (567) $ 1,559,985 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Carrying Value Cash equivalents $ 963,062 $ 32 $ — $ 963,094 Available for sale: U.S. government and agency obligations 372,244 1 (3,239) 369,006 Corporate obligations 520,619 521 (714) 520,426 State and municipal obligations 10,308 — (96) 10,212 Certificates of deposit 12,012 — (2) 12,010 Mortgage-backed securities 154,167 46 (156) 154,057 Asset backed securities 59,289 — — 59,289 Other 386 — (14) 372 Total available-for-sale securities 1,129,025 568 (4,221) 1,125,372 Held to maturity: U.S. government and agency obligations 6,622 — (158) 6,464 Certificates of deposit 1,936 — — 1,936 Total held-to-maturity securities 8,558 — (158) 8,400 Total investments $ 2,100,645 $ 600 $ (4,379) $ 2,096,866
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense	The following table shows the components of the change in medical costs payable for the six months ended June 30 (in thousand s) : June 30, 2023 2022 Medical costs payable - January 1 $ 116,021 $ 6,764 Incurred related to: Current year 504,307 312,339 Prior year 1,029 (2,089) Total incurred 505,336 310,250 Paid related to: Current year 347,629 210,452 Prior year 93,873 4,547 Total paid 441,502 214,999 Medical costs payable - June 30 $ 179,855 $ 102,015 The table below details the components making up the medical costs payable as of June 30 (in thousand s) : June 30, 2023 2022 Provider incentive payable $ 27,884 $ — Incurred but not reported (IBNR) 151,971 102,015 Total medical costs payable $ 179,855 $ 102,015 table below details the components making up the medical costs payable within current liabilities of discontinued operations (in thousands) : Bright HealthCare - Commercial Bright HealthCare June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 Claims unpaid $ 49,474 $ 60,856 $ 41,236 $ 41,188 Provider incentive payable 1,454 310 31,424 40,908 Claims adjustment expense liability 6,993 46,490 4,981 6,732 Incurred but not reported (IBNR) 40,562 583,564 173,628 201,468 Total medical costs payable of discontinued operations $ 98,483 $ 691,220 $ 251,269 $ 290,296 The following table shows the components of the change in medical costs payable for the six months ended June 30 (in thousand s) : Bright Health Care 2023 2022 Medical costs payable - January 1 $ 290,296 $ 240,854 Incurred related to: Current year 810,631 747,953 Prior year 16,058 8,662 Total incurred 826,689 756,615 Paid related to: Current year 602,338 523,662 Prior year 263,378 206,329 Total paid 865,716 729,991 Medical costs payable - June 30 $ 251,269 $ 267,478

ORGANIZATION AND BASIS OF PRE_4

ORGANIZATION AND BASIS OF PRESENTATION - Narrative (Details)				1 Months Ended	3 Months Ended				6 Months Ended
	Aug. 04, 2023 USD ($) $ / shares shares	May 19, 2023 $ / shares shares	May 04, 2023 shares	Oct. 31, 2022 USD ($)	Jun. 30, 2023 USD ($) segment $ / shares shares	Mar. 31, 2023 shares	Jun. 30, 2022 USD ($) shares	Mar. 31, 2022 shares	Jun. 30, 2023 USD ($) business segment $ / shares	Jun. 30, 2022 USD ($)	Dec. 31, 2022 $ / shares
Organization and Basis of Presentation [Line Items]
Number of market facing business | business									2
Number of reportable segments | segment					4				2
Net loss					$ (88,627,000)		$ (251,330,000)		$ (258,088,000)	$ (431,959,000)
Proceeds from sale of stock				$ 175,000,000
Reverse stock splits (in shares) | shares		0.8			0.8	0.8	0.8	0.8
Maximum expected duration of effective time of the reverse stock split			1 year
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001			$ 0.0001				$ 0.0001		$ 0.0001
Medical costs					$ 245,160,000		$ 130,793,000		$ 505,280,000	310,249,000
Revision of Prior Period, Adjustment
Organization and Basis of Presentation [Line Items]
Premium revenue							54,900,000			113,200,000
Medical costs							$ 54,900,000			$ 113,200,000
Minimum
Organization and Basis of Presentation [Line Items]
Reverse stock splits (in shares) | shares			0.0666666667
Discontinued Operations, Held-for-Sale | Brand New Day and Central Health Plan
Organization and Basis of Presentation [Line Items]
Total consideration					600,000,000				600,000,000
Subsequent Event | Penny Warrants
Organization and Basis of Presentation [Line Items]
Exercise price of warrants (usd per share) | $ / shares	$ 0.01
Warrants to purchase our common stock | shares	1,656,789
Revolving Credit Facility | Line of Credit
Organization and Basis of Presentation [Line Items]
Revolving credit facility					$ 350,000,000				$ 350,000,000
Revolving Credit Facility | Line of Credit | Subsequent Event
Organization and Basis of Presentation [Line Items]
Debt instrument, covenant subject to a minimum liquidity	$ 25,000,000
Revolving Credit Facility | Line of Credit | Delayed Draw Term Loan | Subsequent Event
Organization and Basis of Presentation [Line Items]
Line of credit amount	$ 60,000,000
Debt instrument, term	9 months
Debt instrument, interest rate, stated percentage	15%

ORGANIZATION AND BASIS OF PRE_5

ORGANIZATION AND BASIS OF PRESENTATION - Schedule of Operating Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Compensation and fringe benefits	$ 42,413	$ 55,497	$ 101,037	$ 125,008
Professional fees	13,771	6,962	19,619	15,745
Marketing and selling expenses	630	842	1,204	2,270
General and administrative expenses	7,766	5,999	15,223	13,917
Other operating expenses	5,700	9,697	12,715	18,845
Total operating costs	$ 70,280	$ 78,997	$ 149,798	$ 175,785

RESTRUCTURING CHARGES - Schedul

RESTRUCTURING CHARGES - Schedule of Restructuring and Related Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Restructuring Cost and Reserve [Line Items]
Employee termination benefits	$ 1,387	$ 2,604	$ 621	$ 8,701
Long-lived asset impairments	0	0	880	0
Contract termination and other costs	(102)	189	85	956
Total discontinued operations restructuring charges	1,285	2,793	1,586	9,657
Care Delivery
Restructuring Cost and Reserve [Line Items]
Employee termination benefits	0	0	(44)	0
Long-lived asset impairments	0	0	0	0
Contract termination and other costs	0	0	0	0
Total discontinued operations restructuring charges	0	0	(44)	0
Care Solutions
Restructuring Cost and Reserve [Line Items]
Employee termination benefits	0	0	3	0
Long-lived asset impairments	0	0	0	0
Contract termination and other costs	0	0	0	0
Total discontinued operations restructuring charges	0	0	3	0
Corporate & Eliminations
Restructuring Cost and Reserve [Line Items]
Employee termination benefits	1,387	2,604	662	8,701
Long-lived asset impairments	0	0	880	0
Contract termination and other costs	(102)	189	85	956
Total discontinued operations restructuring charges	$ 1,285	$ 2,793	$ 1,627	$ 9,657

RESTRUCTURING CHARGES - Narrati

RESTRUCTURING CHARGES - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Restructuring and Related Activities [Abstract]
Long-lived asset impairments	$ 0	$ 0	$ 880	$ 0

RESTRUCTURING CHARGES - Sched_2

RESTRUCTURING CHARGES - Schedule of Restructuring Reserve by Type of Cost (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 24,077
Charges	706
Cash payments	(17,020)
Ending Balance	7,763
Employee Termination Benefits
Restructuring Reserve [Roll Forward]
Beginning Balance	24,077
Charges	621
Cash payments	(16,935)
Ending Balance	7,763
Contract Termination Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Charges	85
Cash payments	(85)
Ending Balance	$ 0

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Goodwill [Roll Forward]
Gross Carrying Amount	$ 401,385	$ 401,385
Cumulative Impairment	0	0
Care Delivery
Goodwill [Roll Forward]
Gross Carrying Amount	401,385	401,385
Cumulative Impairment	$ 0	$ 0

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 401,385,000		$ 401,385,000		$ 401,385,000
Impairment of intangible assets	0	$ 0	0	$ 0
Amortization of intangible assets	2,900,000	$ 6,200,000	5,900,000	$ 12,400,000
Care Delivery
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 0		$ 0		$ 0

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Schedule of Definite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 128,382	$ 128,382
Accumulated Amortization	29,298	23,431
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	80,021	80,021
Accumulated Amortization	21,910	17,655
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	48,361	48,361
Accumulated Amortization	$ 7,388	$ 5,776

GOODWILL AND INTANGIBLE ASSET_5

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Asset Amortization Expense (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023 (July-December)	$ 5,846
2024	11,574
2025	11,574
2026	11,574
2027	11,574
2028	$ 10,295

MEDICAL COSTS PAYABLE - Change

MEDICAL COSTS PAYABLE - Change in Medical Costs Payable (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Medical costs payable - January 1	$ 116,021	$ 6,764
Incurred related to:
Current year	504,307	312,339
Prior year	1,029	(2,089)
Total incurred	505,336	310,250
Paid related to:
Current year	347,629	210,452
Prior year	93,873	4,547
Total paid	441,502	214,999
Medical costs payable - June 30	$ 179,855	$ 102,015

MEDICAL COSTS PAYABLE - Narrati

MEDICAL COSTS PAYABLE - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Insurance [Abstract]
Medical costs payable, increase (decrease) to prior years	$ 1	$ (2.1)

MEDICAL COSTS PAYABLE - Compone

MEDICAL COSTS PAYABLE - Components of Medical Costs Payable (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Insurance [Abstract]
Provider incentive payable	$ 27,884		$ 0
Incurred but not reported (IBNR)	151,971		102,015
Total medical costs payable	$ 179,855	$ 116,021	$ 102,015	$ 6,764

SHORT-TERM BORROWINGS (Details)

SHORT-TERM BORROWINGS (Details) - USD ($)	Aug. 04, 2023	Jun. 30, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Short-term borrowings		$ 303,947,000	$ 303,947,000
Letters of credit outstanding		30,700,000
Revolving Credit Facility | Line of Credit
Line of Credit Facility [Line Items]
Revolving credit facility		350,000,000
Short-term borrowings		$ 303,900,000	$ 303,900,000
Effective annual interest rate		10.19%
Revolving Credit Facility | Line of Credit | Subsequent Event
Line of Credit Facility [Line Items]
Debt instrument, covenant subject to a minimum liquidity	$ 25,000,000
Revolving Credit Facility | Line of Credit | Delayed Draw Term Loan | Subsequent Event
Line of Credit Facility [Line Items]
Debt instrument, face amount	$ 60,000,000
Debt instrument, term	9 months
Debt instrument, interest rate, stated percentage	15%

SHARE-BASED COMPENSATION - Narr

SHARE-BASED COMPENSATION - Narrative (Details) $ in Millions	3 Months Ended	6 Months Ended
	Sep. 30, 2021	Jun. 30, 2023 USD ($) vestingTranche shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares) | shares		1,700,000
Number of shares available for grant (in shares) | shares		300,000
Granted (in shares) | shares		0
Unrecognized compensation expense | $		$ 17.7
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $		$ 24.5
Vesting period	3 years
Option grants expiration	10 years
Granted (in shares) | shares		0
Unrecognized compensation expense, weighted average recognition period		1 year 7 months 6 days
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $		$ 10.8
Vesting period		3 years
Unrecognized compensation expense, weighted average recognition period		1 year 9 months 18 days
Unrecognized compensation expense, other than options | $		$ 44.3
Granted (in shares) | shares		964,000
Restricted stock units | Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
PSU's
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $		$ 13.8
Unrecognized compensation expense, weighted average recognition period		1 year
Unrecognized compensation expense, other than options | $		$ 24.6
Granted (in shares) | shares		0
PSU's | IPO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares		183,750,000,000
Number of vesting tranches (in vesting tranches) | vestingTranche		4
Service period		3 years
Tranche One | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting				25%
Vesting period				1 year
Tranche Two | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				36 months
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $		$ 49.1	$ 53.1

SHARE-BASED COMPENSATION - Sche

SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Shares
Beginning balance (in shares)	804
Granted (in shares)	0
Exercised (in shares)	0
Forfeited (in shares)	(26)
Expired (in shares)	(58)
Ending balance (in shares)	720	804
Weighted-Average Exercise Price
Beginning balance (in dollars per share)	$ 145.60
Granted (in dollars per share)	0
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	220.21
Expired (in dollars per share)	151.36
Ending balance (in dollars per share)	$ 142.13	$ 145.60
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Weighted-Average Remaining Contractual Life (In Years)	5 years 2 months 12 days	6 years 8 months 12 days
Aggregate Intrinsic Value	$ 569	$ 6,560

SHARE-BASED COMPENSATION - Sc_2

SHARE-BASED COMPENSATION - Schedule of RSU and PSU Activity (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Restricted stock units
Number of Awards
Beginning balance (in shares) | shares	470
Granted (in shares) | shares	964
Vested (in shares) | shares	(94)
Forfeited (in shares) | shares	(232)
Ending balance (in shares) | shares	1,108
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 189.88
Granted (in dollars per share) | $ / shares	32.24
Vested (in dollars per share) | $ / shares	129.70
Forfeited (in dollars per share) | $ / shares	101.45
Ending balance (in dollars per share) | $ / shares	$ 72.57
PSU's
Number of Awards
Beginning balance (in shares) | shares	131
Granted (in shares) | shares	0
Forfeited (in shares) | shares	0
Ending balance (in shares) | shares	131
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 744
Granted (in dollars per share) | $ / shares	0
Forfeited (in dollars per share) | $ / shares	0
Ending balance (in dollars per share) | $ / shares	$ 744

REDEEMABLE CONVERTIBLE PREFER_2

REDEEMABLE CONVERTIBLE PREFERRED STOCK (Details) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Oct. 17, 2022 USD ($) tradingDay $ / shares shares	Jan. 03, 2022 USD ($) tradingDay $ / shares shares	Oct. 31, 2022 USD ($)	Mar. 31, 2022 USD ($) shares	Jun. 30, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares
Class of Stock [Line Items]
Issuance of preferred stock (in shares) | shares				750,000
Issuance of preferred stock | $				$ 747,481
Proceeds from sale of stock | $			$ 175,000
Series A Preferred Stock
Class of Stock [Line Items]
Issuance of preferred stock (in shares) | shares		750,000
Convertible preferred stock, par value (in dollars per share)		$ 0.0001			$ 0.0001	$ 0.0001
Issuance of preferred stock | $		$ 750,000
Redemption price (in dollars per share)		$ 1,000
Temporary equity, liquidation preference (in USD per share)		$ 1,000
Dividend rate		5%
Accretion to redemption value | $					$ 57,600	$ 37,900
Conversion price (in dollars per share)		$ 364
Temporary equity, conversion threshold, volume weighted average price of common stock percentage		175%
Number of threshold trading days | tradingDay		20
Number of consecutive trading days | tradingDay		30
Multiplier for accrued and unpaid dividends, before seventh anniversary		105%
Multiplier for accrued and unpaid dividends, after seventh anniversary		100%
Liquidation preference		105%
Series B Preferred Stock
Class of Stock [Line Items]
Convertible preferred stock, par value (in dollars per share)					$ 0.0001	$ 0.0001
Temporary equity, liquidation preference (in USD per share)	$ 1,000
Dividend rate	5%
Accretion to redemption value | $					$ 6,200	$ 1,800
Conversion price (in dollars per share)	$ 113.60	$ 325.32
Temporary equity, conversion threshold, volume weighted average price of common stock percentage	287%
Number of threshold trading days | tradingDay	20
Number of consecutive trading days | tradingDay	30
Multiplier for accrued and unpaid dividends, before seventh anniversary	105%
Multiplier for accrued and unpaid dividends, after seventh anniversary	100%
Liquidation preference	105%
Number of shares issued (in shares) | shares	175,000
Preferred stock, par value (in dollars per share)	$ 0.0001
Proceeds from sale of stock | $	$ 175,000
Price per share of stock (in dollars per share)	$ 1,000

NET LOSS PER SHARE - Schedule o

NET LOSS PER SHARE - Schedule of Net Loss Per share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Loss from continuing operations, net noncontrolling interests and accrued preferred stock dividends		$ (68,070)	$ (107,559)	$ (139,432)	$ (252,680)
Loss from discontinued operations		(56,935)	(176,568)	(172,478)	(235,619)
Net loss attributable to Bright Health Group, Inc. common shareholders		$ (125,005)	$ (284,127)	$ (311,910)	$ (488,299)
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic (in shares)	[1]	7,962	7,865	7,928	7,862
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, diluted (in shares)	[1]	7,962	7,865	7,928	7,862
Basic and diluted loss per share attributable to Bright Health Group, Inc. common shareholders
Continuing operations, basic (in dollars per share)		$ (8.55)	$ (13.68)	$ (17.59)	$ (32.14)
Continuing operations, diluted (in dollars per share)		(8.55)	(13.68)	(17.59)	(32.14)
Discontinued operations, basic (in dollars per share)		(7.15)	(22.45)	(21.76)	(29.97)
Discontinued operations, diluted (in dollars per share)		(7.15)	(22.45)	(21.76)	(29.97)
Net loss per share attributable to common stockholders, basic (in dollars per share)		(15.70)	(36.13)	(39.35)	(62.11)
Net loss per share attributable to common stockholders, diluted (in dollars per share)		$ (15.70)	$ (36.13)	$ (39.35)	$ (62.11)
[1]*Shares have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 80 reverse stock split

NET LOSS PER SHARE - Schedule_2

NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded From Net Loss Per Share (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	5,909	3,423
Redeemable convertible preferred stock (as converted to common stock)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	4,081	2,112
Stock options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	720	853
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	1,108	458

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Loss contingency, damages paid, value	$ 0	$ 0
Letters of credit outstanding	$ 30,700,000

SEGMENTS AND GEOGRAPHIC INFOR_3

SEGMENTS AND GEOGRAPHIC INFORMATION - Narrative (Details) member in Thousands, consumer in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023 member consumer primaryCareClinic segment	Jun. 30, 2023 primaryCareClinic segment member consumer
Segment Reporting Information [Line Items]
Number of operating segments		2
Number of reportable segments	4	2
Care Delivery
Segment Reporting Information [Line Items]
Number of primary care clinics | primaryCareClinic	71	71
Number of individuals served | consumer	340	340
Care Solutions
Segment Reporting Information [Line Items]
Number of individuals served | member	65	65

SEGMENTS AND GEOGRAPHIC INFOR_4

SEGMENTS AND GEOGRAPHIC INFORMATION - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
ACO REACH revenue	$ 236,994	$ 137,205	$ 476,801	$ 320,002
Investment income (loss)	2	(16,238)	10	(57,149)
Total revenue	297,982	149,340	598,532	330,104
Operating income (loss)	(23,414)	(71,519)	(68,286)	(181,923)
Depreciation and amortization	4,671	8,276	10,154	16,336
Restructuring charges	1,285	2,793	1,586	9,657
Nonrelated Party
Segment Reporting Information [Line Items]
Total revenue	297,982	149,340	598,532	330,104
Affiliated Entity
Segment Reporting Information [Line Items]
Total revenue	0	0	0	0
Capitated revenue
Segment Reporting Information [Line Items]
Revenue	49,764	17,641	99,312	46,289
Service revenue
Segment Reporting Information [Line Items]
Revenue	11,222	10,732	22,409	20,962
Corporate & Eliminations
Segment Reporting Information [Line Items]
ACO REACH revenue	0	0	0	0
Investment income (loss)	2	(16,238)	10	(57,149)
Total revenue	(5,772)	(220,509)	(7,959)	(629,540)
Operating income (loss)	(37,441)	(71,646)	(87,440)	(164,163)
Depreciation and amortization	1,493	1,907	3,844	3,591
Restructuring charges	1,285	2,793	1,586	9,657
Corporate & Eliminations | Nonrelated Party
Segment Reporting Information [Line Items]
Total revenue	2	(16,238)	10	(57,149)
Corporate & Eliminations | Affiliated Entity
Segment Reporting Information [Line Items]
Total revenue	(5,774)	(204,271)	(7,969)	(572,391)
Corporate & Eliminations | Capitated revenue
Segment Reporting Information [Line Items]
Revenue	0	0	0	0
Corporate & Eliminations | Service revenue
Segment Reporting Information [Line Items]
Revenue	0	0	0	0
Care Delivery
Segment Reporting Information [Line Items]
Restructuring charges	0	0	(44)	0
Care Delivery | Operating Segments
Segment Reporting Information [Line Items]
ACO REACH revenue	0	0	0	0
Investment income (loss)	0	0	0	0
Total revenue	66,068	232,603	128,747	639,590
Operating income (loss)	11,031	(698)	17,667	(22,749)
Depreciation and amortization	3,178	6,369	6,310	12,745
Restructuring charges	0	0	0	0
Care Delivery | Operating Segments | Nonrelated Party
Segment Reporting Information [Line Items]
Total revenue	60,294	28,332	120,778	67,199
Care Delivery | Operating Segments | Affiliated Entity
Segment Reporting Information [Line Items]
Total revenue	5,774	204,271	7,969	572,391
Care Delivery | Operating Segments | Capitated revenue
Segment Reporting Information [Line Items]
Revenue	49,764	17,641	99,312	46,289
Care Delivery | Operating Segments | Service revenue
Segment Reporting Information [Line Items]
Revenue	10,530	10,691	21,466	20,910
Care Solutions
Segment Reporting Information [Line Items]
Restructuring charges	0	0	3	0
Care Solutions | Operating Segments
Segment Reporting Information [Line Items]
ACO REACH revenue	236,994	137,205	476,801	320,002
Investment income (loss)	0	0	0	0
Total revenue	237,686	137,246	477,744	320,054
Operating income (loss)	2,996	825	1,487	4,989
Depreciation and amortization	0	0	0	0
Restructuring charges	0	0	0	0
Care Solutions | Operating Segments | Nonrelated Party
Segment Reporting Information [Line Items]
Total revenue	237,686	137,246	477,744	320,054
Care Solutions | Operating Segments | Affiliated Entity
Segment Reporting Information [Line Items]
Total revenue	0	0	0	0
Care Solutions | Operating Segments | Capitated revenue
Segment Reporting Information [Line Items]
Revenue	0	0	0	0
Care Solutions | Operating Segments | Service revenue
Segment Reporting Information [Line Items]
Revenue	$ 692	$ 41	$ 943	$ 52

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (892)	$ 2,904	$ 367	$ 12,885

REDEEMABLE NONCONTROLLING INT_3

REDEEMABLE NONCONTROLLING INTEREST (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance	$ 223,503	$ 219,758	$ 143,011	$ 128,407
Earnings attributable to noncontrolling interest	3,139	1,421	3,625	(2,681)
Distribution to noncontrolling interest holders	(3,147)	(1,805)	(1,894)	0
Measurement adjustment	21,066	4,129	19,712	17,285
Ending balance	$ 244,561	$ 223,503	$ 164,454	$ 143,011

ACO REACH - Narrative (Details)

ACO REACH - Narrative (Details) - directContractingEntity		6 Months Ended
	Jan. 01, 2022	Jun. 30, 2023
Direct Contracting [Abstract]
Number of direct contracting arrangements	3
Number of entities elected to participate in stop-loss arrangement		2
Number of entities elected to third-party coverage		1
Threshold of performance year benchmark		25%

ACO REACH - Schedule Of Perform

ACO REACH - Schedule Of Performance Guarantees (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Direct Contracting [Abstract]
ACO REACH performance year receivable	$ 623,609		$ 623,609		$ 99,181
ACO REACH performance year obligation	474,700		474,700		0
Out-of-network claims incurred	144,300		144,300		$ 1,200
Amortization of ACO REACH performance year receivable	249,449	$ 156,808	424,972	$ 231,935
ACO Reach, Performance Year Obligation, Amortization	234,893	164,404	474,700	347,201
ACO REACH revenue	236,994	$ 137,205	476,801	$ 320,002
Amortization of ACO REACH prior year receivable	$ 99,200		$ 99,200

DISCONTINUED OPERATIONS - Narra

DISCONTINUED OPERATIONS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Restructuring charges	$ 1,285	$ 2,793	$ 1,586	$ 9,657
Discontinued Operations, Held-for-Sale | Brand New Day and Central Health Plan
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total consideration	600,000		600,000
Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Risk adjustment payable	1,954,815		1,954,815		$ 1,943,890
Discontinued Operations | Bright HealthCare - Commercial
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Risk adjustment payable	1,953,502		1,953,502		1,942,643
Discontinued Operations | Bright HealthCare
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Risk adjustment payable	1,313		1,313		1,247
Discontinued Operations | Fair Value, Inputs, Level 1 | Bright HealthCare - Commercial
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash, cash equivalents, and short-term investments	1,500,000		1,500,000		1,300,000
Discontinued Operations | Fair Value, Inputs, Level 2 | Bright HealthCare - Commercial
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash, cash equivalents, and short-term investments	$ 53,200		$ 53,200		$ 826,000

DISCONTINUED OPERATIONS - Sched

DISCONTINUED OPERATIONS - Schedule of Statement of Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Net loss from discontinued operations	$ (56,935)	$ (176,568)	$ (172,478)	$ (235,619)
Discontinued Operations
Revenue:
Premium revenue	428,178	1,364,835	882,261	2,958,335
Service revenue	0	2,113	2,413	4,312
Investment income (loss)	21,520	5,486	42,449	6,297
Other income				799
Total revenue from discontinued operations	449,698	1,372,434	927,123	2,969,743
Operating expenses:
Medical costs	414,702	1,214,789	889,441	2,559,037
Operating costs	90,466	322,541	204,288	636,412
Intangible assets impairment		6,720		6,720
Depreciation and amortization	1,465	4,952	5,872	9,934
Total operating expenses from discontinued operations	506,633	1,549,002	1,099,601	3,212,103
Operating loss from discontinued operations	(56,935)	(176,568)	(172,478)	(242,360)
Interest expense	0	0	0	0
Loss from discontinued operations before income taxes	(56,935)	(176,568)	(172,478)	(242,360)
Income tax expense (benefit)	0	0	0	(6,741)
Net loss from discontinued operations	(56,935)	(176,568)	(172,478)	(235,619)
Discontinued Operations | Bright HealthCare - Commercial
Revenue:
Premium revenue	(15,354)	961,650	(14,588)	2,141,963
Service revenue	0	34	30	70
Investment income (loss)	21,120	5,462	42,011	6,250
Other income				0
Total revenue from discontinued operations	5,766	967,146	27,453	2,148,283
Operating expenses:
Medical costs	14,588	858,347	60,602	1,804,267
Operating costs	35,859	278,878	91,293	544,378
Intangible assets impairment		6,720		6,720
Depreciation and amortization	0	0	0	145
Total operating expenses from discontinued operations	50,447	1,143,945	151,895	2,355,510
Operating loss from discontinued operations	(44,681)	(176,799)	(124,442)	(207,227)
Interest expense	0	0	0	0
Loss from discontinued operations before income taxes	(44,681)	(176,799)	(124,442)	(207,227)
Income tax expense (benefit)	0	0	0	(2)
Net loss from discontinued operations	(44,681)	(176,799)	(124,442)	(207,225)
Discontinued Operations | Bright HealthCare
Revenue:
Premium revenue	443,532	403,185	896,849	816,372
Service revenue	0	0	0	0
Investment income (loss)	400	24	438	47
Other income				0
Total revenue from discontinued operations	443,932	403,209	897,287	816,419
Operating expenses:
Medical costs	400,114	356,442	828,839	754,770
Operating costs	54,289	40,181	110,628	83,502
Intangible assets impairment		0		0
Depreciation and amortization	1,465	4,416	5,872	8,875
Total operating expenses from discontinued operations	455,868	401,039	945,339	847,147
Operating loss from discontinued operations	(11,936)	2,170	(48,052)	(30,728)
Interest expense	0	0	0	0
Loss from discontinued operations before income taxes	(11,936)	2,170	(48,052)	(30,728)
Income tax expense (benefit)	0	0	0	(6,741)
Net loss from discontinued operations	(11,936)	2,170	(48,052)	(23,987)
Discontinued Operations | Other
Revenue:
Premium revenue	0	0	0	0
Service revenue	0	2,079	2,383	4,242
Investment income (loss)	0	0	0	0
Other income				799
Total revenue from discontinued operations	0	2,079	2,383	5,041
Operating expenses:
Medical costs	0	0	0	0
Operating costs	318	3,482	2,367	8,532
Intangible assets impairment		0		0
Depreciation and amortization	0	536	0	914
Total operating expenses from discontinued operations	318	4,018	2,367	9,446
Operating loss from discontinued operations	(318)	(1,939)	16	(4,405)
Interest expense	0	0	0	0
Loss from discontinued operations before income taxes	(318)	(1,939)	16	(4,405)
Income tax expense (benefit)	0	0	0	2
Net loss from discontinued operations	$ (318)	$ (1,939)	$ 16	$ (4,407)

DISCONTINUED OPERATIONS - Sch_2

DISCONTINUED OPERATIONS - Schedule of Cash Flows From Operating and Investing Activities for Discontinued Operations (Details) - Discontinued Operations - Bright HealthCare - Commercial $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash used in operating activities - discontinued operations	$ (667,237)
Cash provided by investing activities - discontinued operations	$ 157,048

DISCONTINUED OPERATIONS - Sch_3

DISCONTINUED OPERATIONS - Schedule of Assets and Liabilities of Discontinued Operations (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Current assets of discontinued operations	$ 3,030,870	$ 3,187,464
Other assets:
Other assets of discontinued operations	0	529,117
Current liabilities:
Current liabilities of discontinued operations	2,584,890	3,157,236
Discontinued Operations
Current assets:
Cash and cash equivalents	1,252,781	1,715,284
Short-term investments	995,414	1,133,772
Accounts receivable, net of allowance	50,771	65,111
Prepaids and other current assets	214,282	273,297
Property, equipment and capitalized software, net	19,948
Goodwill	358,693
Intangible assets, net	138,981
Current assets of discontinued operations	3,030,870	3,187,464
Other assets:
Property, equipment and capitalized software, net		21,298
Goodwill		358,693
Intangible assets, net		144,131
Other non-current assets		4,995
Other assets of discontinued operations		529,117
Total assets of discontinued operations	3,030,870	3,716,581
Current liabilities:
Medical costs payable	349,751	981,517
Accounts payable	47,366	171,565
Risk adjustment payable	1,954,815	1,943,890
Unearned revenue	142,698	242
Other current liabilities	90,260	60,022
Current liabilities of discontinued operations	2,584,890	3,157,236
Total liabilities of discontinued operations	2,584,890	3,157,236
Discontinued Operations | Bright HealthCare - Commercial
Current assets:
Cash and cash equivalents	917,328	1,469,577
Short-term investments	991,106	1,129,800
Accounts receivable, net of allowance	1,915	4,167
Prepaids and other current assets	57,465	187,818
Property, equipment and capitalized software, net	0
Goodwill	0
Intangible assets, net	0
Current assets of discontinued operations	1,967,814	2,791,362
Other assets:
Property, equipment and capitalized software, net		0
Goodwill		0
Intangible assets, net		0
Other non-current assets		0
Other assets of discontinued operations		0
Total assets of discontinued operations	1,967,814	2,791,362
Current liabilities:
Medical costs payable	98,482	691,221
Accounts payable	38,802	160,707
Risk adjustment payable	1,953,502	1,942,643
Unearned revenue	0	0
Other current liabilities	20,738	19,373
Current liabilities of discontinued operations	2,111,524	2,813,944
Total liabilities of discontinued operations	2,111,524	2,813,944
Discontinued Operations | Bright HealthCare
Current assets:
Cash and cash equivalents	335,453	244,616
Short-term investments	4,308	3,972
Accounts receivable, net of allowance	48,856	59,308
Prepaids and other current assets	156,817	85,479
Property, equipment and capitalized software, net	19,948
Goodwill	358,693
Intangible assets, net	138,981
Current assets of discontinued operations	1,063,056	393,375
Other assets:
Property, equipment and capitalized software, net		21,298
Goodwill		358,693
Intangible assets, net		144,131
Other non-current assets		4,995
Other assets of discontinued operations		529,117
Total assets of discontinued operations	1,063,056	922,492
Current liabilities:
Medical costs payable	251,269	290,296
Accounts payable	8,564	10,858
Risk adjustment payable	1,313	1,247
Unearned revenue	142,698	0
Other current liabilities	69,522	40,002
Current liabilities of discontinued operations	473,366	342,403
Total liabilities of discontinued operations	$ 473,366	342,403
Discontinued Operations | Other
Current assets:
Cash and cash equivalents		1,091
Short-term investments		0
Accounts receivable, net of allowance		1,636
Prepaids and other current assets		0
Current assets of discontinued operations		2,727
Other assets:
Property, equipment and capitalized software, net		0
Goodwill		0
Intangible assets, net		0
Other non-current assets		0
Other assets of discontinued operations		0
Total assets of discontinued operations		2,727
Current liabilities:
Medical costs payable		0
Accounts payable		0
Risk adjustment payable		0
Unearned revenue		242
Other current liabilities		647
Current liabilities of discontinued operations		889
Total liabilities of discontinued operations		$ 889

DISCONTINUED OPERATIONS - Sch_4

DISCONTINUED OPERATIONS - Schedule of Restructuring and Related Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Employee termination benefits	$ 1,387	$ 2,604	$ 621	$ 8,701
Long-lived asset impairments	0	0	880	0
Contract termination and other costs	(102)	189	85	956
Total discontinued operations restructuring charges	1,285	$ 2,793	1,586	9,657
Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Employee termination benefits	213		3,177
Long-lived asset impairments	2,489		7,429
Contract termination and other costs	(1,041)		(989)
Total discontinued operations restructuring charges	$ 1,661		$ 9,617	$ 0

DISCONTINUED OPERATIONS - Sch_5

DISCONTINUED OPERATIONS - Schedule of Restructuring Reserve by Type of Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Restructuring Reserve [Roll Forward]
Beginning Balance			$ 24,077
Charges	$ 1,285	$ 2,793	1,586	$ 9,657
Ending Balance	7,763		7,763
Discontinued Operations
Restructuring Reserve [Roll Forward]
Charges	1,661		9,617	$ 0
Discontinued Operations | Bright HealthCare - Commercial
Restructuring Reserve [Roll Forward]
Beginning Balance			45,106
Charges			2,188
Cash payments			(12,210)
Ending Balance	35,084		35,084
Employee Termination Benefits
Restructuring Reserve [Roll Forward]
Beginning Balance			24,077
Ending Balance	7,763		7,763
Employee Termination Benefits | Discontinued Operations | Bright HealthCare - Commercial
Restructuring Reserve [Roll Forward]
Beginning Balance			16,053
Charges			3,177
Cash payments			(12,409)
Ending Balance	6,821		6,821
Contract Termination Costs
Restructuring Reserve [Roll Forward]
Beginning Balance			0
Ending Balance	0		0
Contract Termination Costs | Discontinued Operations | Bright HealthCare - Commercial
Restructuring Reserve [Roll Forward]
Beginning Balance			29,053
Charges			(989)
Cash payments			199
Ending Balance	$ 28,263		$ 28,263

DISCONTINUED OPERATIONS - Sch_6

DISCONTINUED OPERATIONS - Schedule of Investment Securities (Details) - Bright HealthCare - Commercial - Discontinued Operations - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Cash equivalents, Amortized Cost	$ 564,557	$ 963,062
Cash equivalents, Gross Unrealized Gains	14	32
Cash equivalents, Gross Unrealized Losses	0	0
Cash equivalents, Carrying Value	564,571	963,094
Available for sale:
Available-for-Sale, Amortized Cost	989,007	1,129,025
Available-for-Sale, Gross Unrealized Gains	131	568
Available-for-Sale, Gross Unrealized Losses	(454)	(4,221)
Available-for-Sale, Carrying Value	988,684	1,125,372
Held to maturity:
Held to maturity, Amortized Cost	6,843	8,558
Held to maturity, Gross Unrealized Gains	0	0
Held-to-Maturity, Gross Unrealized Losses	(113)	(158)
Held-to-Maturity, Carrying Value	6,730	8,400
Available for sale and held to maturity
Amortized Cost, Total investments	1,560,407	2,100,645
Gross Unrealized Gains, Total investments	145	600
Gross Unrealized Losses, Total investments	(567)	(4,379)
Carrying Value, Total investments	1,559,985	2,096,866
U.S. government and agency obligations
Available for sale:
Available-for-Sale, Amortized Cost	975,759	372,244
Available-for-Sale, Gross Unrealized Gains	128	1
Available-for-Sale, Gross Unrealized Losses	(270)	(3,239)
Available-for-Sale, Carrying Value	975,617	369,006
Held to maturity:
Held to maturity, Amortized Cost	6,512	6,622
Held to maturity, Gross Unrealized Gains	0	0
Held-to-Maturity, Gross Unrealized Losses	(113)	(158)
Held-to-Maturity, Carrying Value	6,399	6,464
Corporate obligations
Available for sale:
Available-for-Sale, Amortized Cost	3,025	520,619
Available-for-Sale, Gross Unrealized Gains	0	521
Available-for-Sale, Gross Unrealized Losses	(27)	(714)
Available-for-Sale, Carrying Value	2,998	520,426
State and municipal obligations
Available for sale:
Available-for-Sale, Amortized Cost	4,169	10,308
Available-for-Sale, Gross Unrealized Gains	0	0
Available-for-Sale, Gross Unrealized Losses	(8)	(96)
Available-for-Sale, Carrying Value	4,161	10,212
Certificates of deposit
Available for sale:
Available-for-Sale, Amortized Cost	3,661	12,012
Available-for-Sale, Gross Unrealized Gains	0	0
Available-for-Sale, Gross Unrealized Losses	0	(2)
Available-for-Sale, Carrying Value	3,661	12,010
Held to maturity:
Held to maturity, Amortized Cost	331	1,936
Held to maturity, Gross Unrealized Gains	0	0
Held-to-Maturity, Gross Unrealized Losses	0	0
Held-to-Maturity, Carrying Value	331	1,936
Mortgage backed securities
Available for sale:
Available-for-Sale, Amortized Cost	1,695	154,167
Available-for-Sale, Gross Unrealized Gains	0	46
Available-for-Sale, Gross Unrealized Losses	(149)	(156)
Available-for-Sale, Carrying Value	1,546	154,057
Asset-backed securities
Available for sale:
Available-for-Sale, Amortized Cost	698	59,289
Available-for-Sale, Gross Unrealized Gains	3	0
Available-for-Sale, Gross Unrealized Losses	0	0
Available-for-Sale, Carrying Value	$ 701	59,289
Other
Available for sale:
Available-for-Sale, Amortized Cost		386
Available-for-Sale, Gross Unrealized Gains		0
Available-for-Sale, Gross Unrealized Losses		(14)
Available-for-Sale, Carrying Value		$ 372

DISCONTINUED OPERATIONS - Sch_7

DISCONTINUED OPERATIONS - Schedule of Incurred Claims and Cumulative Paid Claims (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Claims adjustment expense liability	$ 27,884		$ 0
Total medical costs payable	179,855	$ 116,021	102,015	$ 6,764
Bright HealthCare - Commercial
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Claims unpaid	49,474	60,856
Provider incentive payable	1,454	310
Claims adjustment expense liability	6,993	46,490
Incurred but not reported (IBNR)	40,562	583,564
Discontinued Operations | Bright HealthCare - Commercial
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total medical costs payable	98,483	691,220
Discontinued Operations | Bright HealthCare
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Claims unpaid	41,236	41,188
Provider incentive payable	31,424	40,908
Claims adjustment expense liability	4,981	6,732
Incurred but not reported (IBNR)	173,628	201,468
Total medical costs payable	$ 251,269	$ 290,296	$ 267,478	$ 240,854

DISCONTINUED OPERATIONS - Sch_8

DISCONTINUED OPERATIONS - Schedule of Components of Medical Costs Payable (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Medical costs payable - January 1	$ 116,021	$ 6,764
Incurred related to:
Current year	504,307	312,339
Prior year	1,029	(2,089)
Total incurred	505,336	310,250
Paid related to:
Current year	347,629	210,452
Prior year	93,873	4,547
Total paid	441,502	214,999
Medical costs payable - June 30	179,855	102,015
Discontinued Operations | Bright HealthCare
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Medical costs payable - January 1	290,296	240,854
Incurred related to:
Current year	810,631	747,953
Prior year	16,058	8,662
Total incurred	826,689	756,615
Paid related to:
Current year	602,338	523,662
Prior year	263,378	206,329
Total paid	865,716	729,991
Medical costs payable - June 30	$ 251,269	$ 267,478

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	Aug. 04, 2023	Jun. 30, 2023
Revolving Credit Facility | Line of Credit
Subsequent Event [Line Items]
Revolving credit facility		$ 350,000,000
Subsequent Event | Revolving Credit Facility | Line of Credit
Subsequent Event [Line Items]
Debt instrument, covenant subject to a minimum liquidity	$ 25,000,000
Subsequent Event | Revolving Credit Facility | Delayed Draw Term Loan | Line of Credit
Subsequent Event [Line Items]
Debt instrument, term	9 months
Debt instrument, interest rate, stated percentage	15%
Subsequent Event | Penny Warrants
Subsequent Event [Line Items]
Warrants to purchase our common stock	1,656,789
Subsequent Event | Line of Credit | Delayed Draw Term Loan
Subsequent Event [Line Items]
Revolving credit facility	$ 60,000,000
Subsequent Event | Line of Credit | Revolving Credit Facility | Delayed Draw Term Loan
Subsequent Event [Line Items]
Debt instrument, term	9 months